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ABSTRACT 
Title 
A prospective, controlled study on 131 patients assessing patient safety and nasal function 
outcomes following human olfactory mucosa biopsy as a source of cells for central nervous 
system regeneration during Endoscopic Sinus Surgery (ESS). 
Hypotheses 
The primary hypothesis states; olfactory harvesting is a safe procedure and does not incur a 
reduction in nasal function including the sense of smell when compared to a control group. 
The secondary hypothesis states; ESS improves olfactory outcome in CRS patients with nasal 
polyps (CRSwNP) and CRS without nasal polyps (CRSsNP). 
Materials and Methods 
Full Ethical and Research and Development (R&D) approval was granted;  
Ref: 05/Q0512/103. 131 patients were recruited over a 2 year period and non-randomised into 
the olfactory biopsy and control arms. Statistical significance was accepted at the 5% level 
(<0.05) and powered at 80%. Complication rates as well as patient and surgeon reported 
outcome measures were recorded in each arm both pre operatively and 6 months post 
operatively.  The sense of smell was evaluated using the University of Pennsylvania Smell 
Identification Test (UPSIT).  
Results 
 65 patients underwent superior turbinate biopsy with 66 controls. The complication rate, the 
nasal function and the sense of smell outcomes  of the biopsy group were statistically the 
same when compared  to the control group. In the CRS subgroup analysis the sense of smell 
improved in both groups following ESS but only in the CRSwNP subgroup was it found to be 
significant. 
Conclusions 
The primary hypothesis was shown to be true and demonstrated that patient morbidity and 
beneficial outcomes following harvesting human olfactory nasal mucosa during ESS is 
statistically the same when compared to the control group. The secondary hypothesis was 
equally shown to be true and demonstrated that sinus surgery improved olfaction in both the 
CRSwNP and CRSsNP subgroups but only in the CRSwNP subgroup was the olfactory 
improvement significant. 
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CHAPTER 1 
 
INTRODUCTION 
 
 
The unmet need 
 
Nasal olfactory mucosa is an accessible source of Olfactory Ensheathing Cells (OECs) which 
can be harvested for spinal cord and brachial plexus repair. Current clinical studies utilizing 
OECs in central nervous system (CNS) regeneration have shown promising results 
(1-3)
.  In 
order to move into clinical trials of OECs for nerve repair there is a need to perform patient 
safe olfactory mucosa harvesting 
(4)
. Current evidence suggests that human olfactory mucosal 
biopsies do not have a detrimental effect on the patient’s sense of smell (5;6), however up to 
now a  prospective controlled study measuring olfaction, quality of life as well as patient and 
surgeon reported outcome measurements  has not been performed. In Feron et al, 20 patients 
had undergone olfactory biopsies and their sense of smell also had not deteriorated as 
measured by the UPSIT measurement 
(6)
. In Lanza et al, a retrospective olfactory study was 
performed which evaluated 19 patients who had undergone olfactory biopsies. According to 
their UPSIT findings a reduction in the sense of smell, was not demonstrated 
(5)
. Equally the 
surgical techniques for nasal olfactory harvesting which have been reported in the literature 
have recruited small numbers of patients as well as lacking robust safety, nasal function and 
quality of life analysis 
(7;8)
. 
 
Background/Introduction 
 
OEC yield rates from nasal septum mucosa, which is more accessible than superior turbinate 
mucosa, during routine endoscopic nasal surgery has been explored but unfortunately yield 
rates were low which has spearheaded this thesis 
(9)
. Endonasal techniques for optimizing 
nasal olfactory harvesting have been developed so as to maximize OEC yield rates  and 
current evidence suggests that the superior turbinate is both accessible and also allows for an 
optimal OEC yield 
(4)
. Anatomically human autopsy techniques have demonstrated maximal 
olfactory tissue to be present beneath the cribiform fossa including the superior septum 
however such techniques would prove difficult to replicate during routine nasal surgery 
owing to the likely hood of cerebrospinal fluid (CSF) leakage 
(10)
. Consequently the superior 
turbinate harvesting technique has evolved which utilises the middle section of the superior 
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turbinate. The superior turbinate lies close to the cribiform niche and the intrinsic olfactory 
tissue and will be further described in this thesis 
(4)
. 
 
The quest to repair the human central nervous system (CNS) following trauma remains a 
surgical challenge. The human olfactory system may provide an answer by utilizing the 
regenerative ability of the olfactory ensheathing cell (OEC), which facilitates the natural 
neurogenesis of the human olfactory nerve during the olfactory life cycle and uniquely is the 
only glial cell to facilitate regeneration within the CNS. The concept of utilising OECs for 
CNS repair is predicated on their intrinsic ability to facilitate olfactory neurogenesis and 
supports regenerating axons within the CNS. OECs could be harvested from the olfactory 
bulb however this would be associated with unacceptable risk of stroke, seizure or death 
(11-
13)
, hence a safer alternative is being advocated. 
 
Olfactory ensheathing cells (OECs) are glial cells which specifically support the olfactory 
receptor neurons (ORNs) and are located both in the olfactory bulb of the CNS and the 
olfactory mucosa of the peripheral nervous system (PNS) 
(14-16)
. They were described by 
Doucette in 1984 as a distinct glial cell entity enabling regeneration of the olfactory system 
(17)
. They support, nurture and facilitate regeneration of the olfactory nerves and have the 
unique ability to transgress both PNS and CNS environments
(18)
. They also provide important 
neuro-protective properties and stimulate regeneration through neurotrophic signaling and 
myelination of new axons, providing a continuous channel for the regeneration of new 
olfactory axons 
(12)
. OECs have the unique ability to interact and migrate within the astrocytic 
rich environment of the CNS  and human olfactory bulb 
(19)
 and have been shown to  re-
myelinate de-myelinated CNS axons  
(15;18)
.   
 
 
Spinal cord injury and Glial Scar Formation 
 
The inability for the mammalian CNS to repair itself following injury is thought to be an 
evolutionary safety mechanism so as to prevent catastrophic disorganized re-growth. 
Although, the mammalian brain after injury does exhibit plasticity with the ability to form 
new synapses, unfortunately it is unable to form new axons 
(20;20)
. This inhibitory nature of 
the injured central nervous system is predominately a consequence of the formation of a glial 
scar which contains inhibitory proteins and prevents axonal re-growth 
(21)
. 
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Conversely, the human olfactory system undergoes a regular cycle of neurogenesis whereby 
olfactory neurons have the unique ability to regenerate into the inhibitory CNS environment 
on a regular basis and is facilitated by olfactory ensheathing cells (OECs). This extraordinary 
process offers a potential remedy for CNS regeneration by laying down a non-inhibitory 
pathway and by facilitating regeneration allows neurons to regenerate in the CNS 
(18)
. 
 
Glial scar formation 
 
Glial scar formation occurs as a result of CNS injury through a process of astrocytosis.  
Through the aggregation of astrocytes inhibitory proteins are laid down and include nogo 
amyelin associated glycoprotein and oligodendrocyte myelin glycoprotein 
(21-24)
. Astrocytes 
represent one of the four CNS glial supporting cells which also include oligodendrocytes, 
microglia and olfactory ensheathing cells (OECs). The role of the astrocyte is one of 
protection as well as in the formation of the blood brain barrier. Oligodendrocytes equally 
provide a supportive neuronal role as do microglia within the CNS. OECs are the supportive 
glial cell for the olfactory receptor neurons (ORNs) 
(14;23)
. 
 
Transplantation technology 
 
The ever increasing need to surgically repair the CNS has fuelled the need to harness 
techniques which encourage regeneration and work against the intrinsic inhibitory nature of 
the human CNS. The transplantation of regenerative cells into the injured CNS site is one 
potential solution which has been explored in the injured peripheral nervous system as well as 
being harnessed in treating diseases which require replacement therapy such as Parkinson’s 
disease 
(25;26)
.  The peripheral nervous system (PNS) has an inherent ability for regeneration 
unlike the central nervous system. The process of regeneration in the peripheral nervous 
system is multi-factorial and includes the ability for the regenerating neuronal end plate to 
penetrate and re-grow through the surrounding substrate of a Schwann cell conduit. 
Importantly PNS regeneration is not met with an inhibitory glial scar equivalent
(27;28)
. 
 
The concept of utilizing olfactory ensheathing cells as a source for transplantation is 
predicated on its ability to regenerate into the inhibitory arena of the central nervous system 
and the added advantage of being autologous tissue. The alternative to an autologous 
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transplantation of olfactory tissue would be the transplantation of allogeneic olfactory cells 
but this would require immunosuppression on behalf of the recepient. The key however is 
devising a safe and reproducible olfactory harvesting technique. The process of harvesting 
OECs which were originally sourced from the olfactory bulb in the rat obviously would pose 
significant safety issues in the human albeit a potential calculated risk in a paraplegic patient 
with a burning quest to walk again
(11;13)
. In the human an alternative safer technique involves 
harvesting OECs from the nasal mucosa. Methods of nasal olfactory harvesting which 
significantly reduce the risk of morbidity have been devised and used in autologous 
transplantations in paraplegic patients 
(2;3;7;8)
. 
 
The concept of cellular transplantation of human OECs into an injured spinal cord lesion is 
being developed and trialed 
(1)
. There have been mixed results owing mainly to the lack of 
uniformity and consistency between the different regenerative units pertaining to their 
grafting techniques and protocols. This has lead to difficulty in ascertaining the ideal and 
optimum constituents for OEC grafts. Although it would make sense for a pure OEC graft 
transplantation to be the gold standard, current strategies favour a less pure constituent which 
also contains fibroblasts; based on the possible hypothesis that the 2 cell types are synergistic. 
The estimated number of pure OECs required for human spinal cord transplantation is 
unknown and is obviously dependent on the size of the lesion although it is thought to be 
between the region of 10
7
 and 10
8  (3)
. The reality is that the exact regenerative component of 
the olfactory epithelium is also unknown and may additionally require its basal cell 
constituent 
(26)
. The method of transplantation of OECs into the patient does vary within the 
literature, and  depends on the size of the defect, and includes injecting expanded cultures of 
OECS via micromanipulation whereas in other studies the whole of the olfactory mucosa is 
inserted 
(23)
. The advances in tissue engineering and scaffold implantation technology will 
revolutionise the future paradigms of spinal cord injury treatments 
(29)
. 
 
Origin of OECs 
 
OEC’s show both Schwann cell and Astrocytic cell immunocytochemical properties owing to 
their common glial identity and embryonic origin. OECs are embryonically derived from the 
neural crest as are Schwann cells although until recently they were thought to be derived 
from the olfactory placode 
(30)
.  OECs and Schwann cells both exhibit expression for the 
neurotrophin receptor; the low affinity nerve growth factor receptor p75 NTR  
(31)
, the 
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polyclonal antiglial fibrillary acidic protein anti-GFAP  and S100 beta. As a result both OECs 
and Schwann cells stain positive to these antibodies which makes differentiation challenging 
in vitro and the ability to rule out Schwann cell contamination difficult
(23)
. Recent work has 
shown OECs express smooth muscle actin (SMA) whereas Schwann cells do not express it 
(32)
 and equally the anti-HNK1 antibody is a specific antibody for Schwann cells which has 
been used to determine whether there is evidence of significant trigeminal Schwann cell 
contamination within in-vitro cultures of human nasal OECs
(7)
.   
 
OECs in the olfactory bulb are predominately the same cell type as OECs found in the lamina 
propria of the olfactory mucosa, although subtle differences have been demonstrated. OECs 
residing in the olfactory mucosa possess more migratory properties 
(33)
 and potentially more 
stem cell characteristics 
(34)
. It was initially thought that because rats being macrosmatic (i.e. 
50% of their nasal cavity surface area is dedicated to olfaction) they contained a different cell 
type of OEC to microsmatic humans. However, transplantation of human OECs into an 
immunosuppressed severed rat spinal cord showed integration and remyelination and hence 
demonstrated an equivalent universal cell type 
(26;35)
. 
 
Human Olfactory Receptor Neuron (ORN) and Cribiform plate anatomy 
 
The human olfactory receptor neurons (ORNs) regenerate and replenish themselves every 4 
to 6 weeks through a process of neurogenesis whereby new axons travel back through the 
cribiform foramina of the cribiform fossa and pass into the astrocytic rich CNS environment 
and re-synapse within the olfactory bulb. The ability of OECs to support regenerating axons 
within the CNS  has lead to their use in transplantation technology 
(36;37)
. Olfactory receptor 
neurons are bipolar, ciliated neurons. The proximal end is non-myelinated and then forms 
myelinated bundles of axons called filia olfactoria as they congregate in the lamina propria. 
In the lamina propria the olfactory nerve bundles are immunoreactive to beta tubulin and 
neurofilament. The distal end forms knob like structures which give off cilia-like extensions 
containing receptors, each neuron gives off up to 50 extensions which sit in the mucous layer 
(16)
. The extensions contain the olfactory receptors for which there are approximately 1000 
different types, and each respond to a different type of olfactant. Axel and Buck demonstrated 
that each ORN expressed only one olfactory receptor protein and belong to the family of g 
protein coupled receptors 
(38)
. They also estimated that there were 1000 different genes for the 
olfactory receptors in the human genome. All neurons expressing the same receptor synapse 
 18 
 
on the same olfactory bulb glomerulus.  
 
The proximal olfactory neurons join together and form bundles of axons which then pass 
through the cribiform plate. There are approximately 20 bundles in each cavity. Each 
olfactory bundle pierces through the cribiform plate perforations of the ethmoid bone with 
each measuring less than 1mm in diameter and synapse within the olfactory bulb. As the 
nerves exits through the cribiform fossa they divide into 2 groups; the inner and outer groups. 
The inner group being the larger is distributed along the perpendicular plate and the outer 
group supplies the lateral nasal wall and superior turbinates. The cribiform plate of the 
ethmoid bone is narrow and deeply grooved. It supports the olfactory bulb which continues 
on as the olfactory tract. The cribiform plate consists of two to three rows of perforations 
allowing the olfactory nerves to penetrate. The inner row contains larger perforations but 
fewer in number and allows the passage of the ONs from the septum/perpendicular plate. The 
perpendicular plate is grooved to allow the passage of the ONs. The middle and outer rows 
contain the smallest diameter perforations and supply the roof and the superior turbinates 
(39)
.  
 
Figure 1 
Olfactory nerve bundles piercing the cribiform fossa from the nasal septum 
ONB
ONB=Olfactory Nerve Bundles
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Stem cell regenerative properties of the olfactory system 
 
The human olfactory system undergoes neurogenesis every six weeks inorder to replenish 
ORNs which are exposed to harmful and toxic substances resulting in injury and death and 
this process continues until the age of 72 years 
(40) (18;41)
. Olfactory neurogenesis is a 
combination of regeneration and programmed apoptosis. ORNs are replenished from basal 
cells which are putative stem cells found in the olfactory epithelium. Stem cells by definition 
represent an undifferentiated cell within a multicellular organism which are capable of giving 
rise to indefinitely more cells of the same type and from which certain other kinds of cell 
arise by differentiation 
(18)
.  The other 2 areas within the CNS which are known to undergo 
neurogenesis include the olfactory bulb and hippocampus 
(16)
. However, despite the intrinsic 
ability of neurogenesis within the olfactory system it still remains frustrating that the 
olfactory system itself remains prone to irreversible damage.  
 
The specific cell types within the olfactory epithelium which are involved with the process of 
olfactory neurogenesis include ORNs, OECs and Basal cells. Basal cells act as putative stem 
cells and there are 2 types in the rat; Globose Basal Cells (GBCs) and Horizontal Basal Cells 
(HBCs). The GBCs sit above the HBCs on the epithelial basal lamina superficial to the 
lamina propria. The GBCs are rounder and are involved in the normal replenishment process 
of the ORNs and OECs as well as the sustentacular supporting cells. It is thought the HBCs 
are quiescent but come into play during extreme injury and have the ability to replenish the 
GBCs as well as the ORNs/Glial cells. Hence HBCs are thought to be the true stem cell 
population 
(18)
.  In the human however there appears to be only one type of basal cell which 
morphologically resembles more the rhodent GBC, as opposed to the rodent HBC, and the 
reason why humans only have one basal cell type remains unclear 
(42)
.  
 
The olfactory nerve bundles within the lamina propria are also enveloped by fibroblasts and 
consequently immunostain for beta tubulin and neurofilament. Interestingly it’s difficult to 
determine which combination  of cells within the olfactory epithelium are ideal for 
transplantation however studies have demonstrated that pure isolates are not ideal and instead  
a combination of OECs and fibroblasts exhibit a more favorable regenerative ability. Animal 
studies have shown regeneration is only effective if OECs and fibroblasts are transplanted 
together which is not surprising given fibroblasts play a vital role in connective tissue 
production and supporting OEC function and given the ‘feeder cell’ relationship in vitro (12). 
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The aim however is to ensure the proportions of OECs and fibroblasts are optimal. 
Fibroblasts have been shown to proliferate in the first week of cell culture, OECs in the 
second week and then  over proliferation of fibroblasts in the third week. There are methods 
to amplify OEC cultures which include suppression of fibroblast proliferation using 
cytarabine and antibody-mediated complement killing, separate the cells using fluorescent-
automated cell sorters, implementation of growth factors to encourage the growth of OECs 
and exploring the use of allogenic OEC cell lines 
(4;9;23)
. 
 
 
Harvesting Olfactory Mucosa 
 
The keys to harvesting human olfactory mucosa are to ensure the technique is ‘patient safe’ 
and yet ensures a maximum yield rate of OECs. Technically, the ideal place to harvest human 
OECs is from the areas of highest olfactory receptor and axonal density. This corresponds to 
the area where the distal olfactory bundles exit the nasal cavity near the cribiform plate, 
superior septum and superior turbinate 
(10)
. The surgical challenge is to ensure high yield rates 
of OECs which reside superiorly but without breaching the anterior skull base. If the anterior 
skull base is breached with a resultant cerebrospinal fluid leak, then the patient is exposed to 
the potential risks of meningitis and cerebral damage. Safe techniques have been described in 
the literature with regards to minimising anterior skull base trauma and reducing post 
operative morbidity with regards to loss of smell 
(43)
. Lanza et al also concluded several 
punch biopsies can be taken from the olfactory area without causing detriment to the sense of 
smell, albeit the study contained small numbers and hence it was difficult to draw absolute 
conclusions 
(5)
.   
 
However, surgical harvesting techniques optimizing yield rate of OECs as opposed to 
olfactory mucosa have only been robustly evaluated by Choi et al 
(4)
. Bianco et al had 
assessed the OEC yield rate from 3 superior turbinate biopsies but without significant 
conclusions 
(7)
. OEC yield rates are higher when harvested from the superior turbinate region 
as opposed to the septal area and are equally higher from younger and more sinonasal disease 
free mucosa with OEC yield rates averaging 25% 
(4)
. It must be noted that embryonically the 
olfactory mucosa within the nasal cavity is a continuum but over time and with degeneration 
secondary to age and disease, it is replaced with respiratory epithelium 
(44)
. The limitations of 
OEC harvesting from nasal septal mucosa have been demonstrated particularly in the caudal 
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regions 
(9)
. Interestingly, Choi et al described their optimum OEC yield rates based on the 
calculated percentage covering of a 35mm plate whereby yield rates of more than 50% 
covering were considered large enough to proceed for the treatment of patients 
(9)
.  The 
optimum 50% OEC yield rate is based on earlier rat experimentation models whereby similar 
50% yield rates would contain approximately 1.5 million OECs. In their rat spinal cord lesion 
model approximately 500,000 OECs and 500,000 fibroblasts would be injected into the lesion 
affording improved functional recovery 
(45)
. The human model is based on similar concepts 
but a multiple of 100 as based on Choi et al unpublished data.   
 
Sinonasal Anatomy 
 
The anatomy of the paranasal sinuses is generally well defined and consists of five pairs of 
sinuses; the anterior and posterior ethmoidal, maxillary, frontal and sphenoidal sinuses. 
However, there is variability in the height of the skull base and pnematisation of the sinuses 
which necessitates the need for preoperative CT scanning in order to delineate this variation 
prior to FESS 
(46)
. The skull base does not slope back posteriorly at the same height but 
instead slopes back inferiorly from the frontal sinus ostium to the sphenoid as shown in figure 
2, which is highlighted in the saggital CT image guidance scan. In figure 2 the height of the 
skull base reduces from the frontal sinus anteriorly to the sphenoid sinus posteriorly over a 
distance of 3 cms. The anterior skull base also represents an area of increased weakness 
particularly the lateral lamella of the ethmoid bone 
(46)
. 
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Figure 2 Image Guidance CT scan with saggital image delineating the sloping anterior skull 
base 
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Figure 3 
Coronal CT scan highlighting the asymmetry of the anterior skull base with a significant 
deviation of the septum to the left and a left sided concha bullosa 
O
S
M
CB
SB
M=Maxilla, O=Orbit, CB=Concha Bullosa, 
S=Septum and SB=Skull Base  
 
 
 
 
Olfaction 
 
Olfaction or the sense of smell is the detection of odorants and represents the oldest human 
sense. It is one of Aristotle’s five senses; the other four being taste, vision, sight and touch. 
The olfactory system’s limbic and higher cortical connections play an important role in 
motivation and reward which can stimulate intense, enduring odour memory 
(47;48)
.  
Consequently, in cases of olfactory dysfunction there can be a reduction in quality of life, 
with resultant depression, weight disturbance, social anxiety and social isolation 
(49)
 . Human 
olfaction as well as providing sensual pleasure through the recognition of perfumes and 
memory association also aids in survival, with warning of danger by detection of rotten 
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smells and smokes. There are specific professions which are dependent upon an acute sense 
of smell including chefs and sommeliers/tea tasters. There are tens of thousands of odorants 
and the human nose has the ability to discriminate from 1 trillion odours. However in other 
animals its role is more substantial and acts as a pre requisite for survival facilitating the 
hunting of food, mating, avoiding danger and maternal care 
(50)
.  
 
The nose has 2 main sensory inputs; the detection of odorants and the perception of nasal 
airflow.  The primary function of the nose is to optimize the quality of inspired air and in 
doing so act as an ‘air conditioner device’ enabling the filtration, warming and humidification 
of inspired air. The nose shares its’ air conditioning function’ with the olfactory system 
which consists of 2 organs, each innervating one nasal cavity. Unlike vision and hearing the 
nose shares it sensory function with other functions of the nose. Olfaction requires a fluid 
environment in order to allow the odorants to dissolve and also requires a non-obstructed and 
patent airway 
(51)
.  
 
 
Olfactory physiology and location of olfactory mucosa 
 
There are approximately 10,000,000 olfactory receptor neurons supplying the human 
olfactory mucosa although this is thought to be an under estimation. The total surface area of 
the olfactory epithelium is 2.5cm squared and equates to the size of a postage stamp with 
1.25cm squared in each nasal cavity 
(52)
. The total surface area of the internal mucosal nasal 
cavity is approximately 50cm squared and the olfactory mucosa accounts for 3% in the 
human compared to 50% in the rat. In the dog there are approximately 4 billion olfactory 
receptor cells. The olfactory receptor area lies in the dorsal superior aspect of the nose with 
close proximity to the cribiform plate and anterior skull base and equates to the superior 
turbinate and dorsal septum 
(52)
 . 
 
The exact location of the olfactory mucosa within the nasal cavity remains ill-defined and  
generally shown to be more concentrated in the dorsal aspect of the nose including the 
posterior, superior septum and superior turbinate
(43;53)
. Feron et al, studied 33 healthy subjects 
and found yield rates were higher when biopsies were taken from the superior turbinate 
(43)
. 
Leopold interestingly studied healthy volunteers and found olfactory tissue more anteriorly 
than originally thought which correlated to positive electro olfactograms (EOGs) 
(44)
. It would 
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potentially equally explain why patients could still smell even when their olfactory niche was 
blocked secondary to sinonasal disease. As well as objective electro-olfactograms (EOGs), 
patients also underwent olfactory biopsies which were immunostained for olfactory marker 
protein (OMP) and beta tubulin 3 which is a neurofilament antibody specific for neurons.  
Over 50% stained positive, with some samples only staining positive in the lamina propria 
and not the epithelium signifying olfactory degeneration 
(44)
. Lane et al studied the inferior 
aspect of the superior turbinate and found olfactory neuroepithelium
(53)
. Choi et al, evaluated 
septal mucosa and although olfactory mucosa was successfully harvested the olfactory yield 
rates were deemed too low for potential transplantation as previously described 
(9)
. 
 
Odorants and Olfactory Receptor Genetics 
 
The initial step in olfactory transduction is the movement of odorants from the air phase of 
the nasal cavity into the aqueous phase of the olfactory mucus. Odorants are carried into the 
nasal cavity and through nasal airflow turbulence are distributed superiorly towards the 
olfactory niche. They subsequently dissolve in the mucous layer and attach to a specific 
odorant binding protein. In order for an odor to be perceived ideally it must possess 
molecules with water solubility, high vapor pressure, low polarity and lipophilic activity. 
Most odorants are hydrophobic and not water soluble and hence require odor binding 
proteins. Odors are then coded by specific patterns of ORN action potential neural activity 
either in space or time which leads to the perception of odors 
(54)
. Although the current 
concept of odorant recognition is through shape identification there is increasing evidence 
also supporting molecular vibration 
(55)
.  
 
Buck and Axel described a marked genetic diversity in olfactory receptors and found in 
rodents a large multigene family of ~1000 genes which appear to code for odorant receptor 
proteins with seven trans-membrane domains. However, in humans, more than half of the 
receptor gene families are pseudogenes and through epigenetics and the process of turning 
genes on and off there are approximately 500 functional receptors. Even though each receptor 
cell expresses only one type of olfactory receptor, such cells respond to a wide range of 
odorants. However, a given receptor, though a "generalist," does not respond to all stimuli to 
which another receptor responds, thereby allowing for cross-neuron quality coding 
(38)
 .  
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The olfactory and respiratory epithelium 
 
The olfactory epithelium consists of non ciliated pseudocolumnar epithelium and to the naked 
eye looks identical in colour to the surrounding respiratory epithelium, unlike the rodent 
which exhibits a yellow hue 
(56)
. The cellular composition of the olfactory epithelium consists 
of four types of cell; ORN’s, supporting glial cells; OECs and basal cells. The basal cells 
represent the putative stem cells and are divided into small globose basal cells and horizontal 
basal cells which lie on the basal lamina 
(18)
. The olfactory epithelium in the human is a lot 
thinner compared to the rodent  whereas the lamina propria  is a lot thicker 
(9)
.  
 
Respiratory epithelium is a ciliated pseudostratfied epithelium and each cell contains 
approximately 250 cilia which are 2 to 5 microns in length, Each cilia consists of 9 
microtubules doublets surrounding 2 microtubules and held together by dynein arms. Cilia 
beat with a coordinated biphasic wavelike rhythm called metachronism, 1000 strokes per 
minute with a powered forward stroke and a slow recovery stroke. They transport particles in 
the nose at 20 micrometers per minute and can be objectively investigated using the 
saccharine test with a normal time of 20 minutes 
(51).
 
 
Surgical anatomy of the first olfactory nerve 
 
The first olfactory nerve represents the most caudal olfactory nerve bundle which is often the 
first olfactory nerve bundle identified during surgical dissection piercing the cribiform plate, 
just anterior the anterior ethmoidal nerve.  It lies adjacent to the perpendicular plate and 
septum and is often seen during endoscopic frontal sinus surgery and exposed whilst locating 
the olfactory protuberance during an endoscopic modified Lothrop procedure, as shown in 
figure 4. It represents the anatomical landmark for the olfactory protuberance and hence the 
anterior skull base 
(57)
. 
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Figure 4 
The first Olfactory nerve exiting through the cribiform fossa, identified under the suction tip 
 
 
 
 
Trigeminal innervations 
 
Although olfaction is primarily detected through the first cranial nerve, the fifth, ninth and 
tenth cranial nerves also provide olfactory input. The trigeminal nerve is thought to play a 
role in the modulation of olfactory information, as well as recognition of pungent smells. It 
provides sensation to the inside and outside of the nose as well as perception of nasal airflow 
through its somatosensory innervations 
(58)
. The trigeminal sensory receptors are distributed 
anteriorly in the nares as opposed to the more superiorly localized olfactory receptors in the 
attic of the nasal cavity. Different afferent fibres are involved in the trigeminal mediated 
sensation; ‘C fibres’ transmit dull, burning pain and ‘A fibres’ transmit sharp stinging pain. 
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The first and second divisions of the trigeminal nerve are involved in the sensory provision of 
the nose and are involved in the initiation of the protective feedback mechanism including 
sneezing. The majority of odorants stimulate both the olfactory and trigeminal receptors such 
as nicotine providing concurrent odor perception and stinging. However the odorant Vanillin 
only stimulates the olfactory receptors 
(58)
. The trigeminal anterior ethmoidal nerve is one of 
the first nerve bundles encountered during anterior skull base exploration and is several 
millimeters anterior to the first olfactory nerve.  
 
The vomeronasal organ 
 
The vomeronasal organ (VNO), or organ of Jacobson, is an accessory concentration of 
olfactory tissue. It is located in a 1mm to 3 mm tubule, with an oval orifice, approximately 1 
cm posterior from the caudal septum and 2 to 4 mm off the floor of the nose. It is believed to 
be receptive to pheromones which are responsible for sexual instincts and mood. VMO is 
present in 91% of the population and thought to be a rudimentary organ without neuronal 
connection to the brain 
(59)
. 
 
The Olfactory bulb 
 
The human olfactory bulb (OB) is an elongated evagination of the forebrain which lies on the 
cribiform niche and receives 20 olfactory bundles from each nares. Its function is thought to 
act as a filter of olfactory inputs. Its average volume is 125mm
3
 and shown to be smaller in 
females. The volume of the OB remains ‘plastic’ and varies in size according to its neuronal 
stimulation owing to its intrinsic ability to undergo neurogenesis. It has been shown to be 
smaller in patients with olfactory disorders and equally smaller on the same side of a deviated 
septum with subsequent reduced olfactory stimulation 
(39;60)
.  
 
 
The OB represents a highly organized structure which consists of 5 layers; the outer 
glomerular layer, external plexiform layer, mitral cell layer, internal plexiform layer and the 
granule layer.  The outer glomerular layer is formed from dendritic tangles of mitral cells 
which synapse with excitatory ORNs as well as inhibitory periglomerular and granule cells. 
The olfactory bulb contains on average 5500 glomeruli 
(61)
. ORNs with the same receptors 
diverge onto the same glomerulus. Approximately 10,000,000 ORNs synapse with 5000 
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glomeruli. The mitral cell axonal projections run caudally through the OB structure and onto 
the olfactory cortex
(61)
. 
 
 
 
 
 
Figure 5 
T2 weighted MRI scan highlighting T2 hyperintense olfactory bulbs on the cribiform fossa  
 
 
 
 
 
 
 
 
The olfactory bulbs can be seen as evaginations of the anterior cerebral cortex in the above 
T2 weighted MRI scans. In figure 5 the olfactory bulbs are T2 hyperintense and lie on the 
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cribiform fossa and in figure 6 the extension of the olfactory bulb and its olfactory neurons 
can be seen coalescing onto the superior turbinate.  
 
 
 
Figure 6 
T2 MRI scan highlighting hyperintense olfactory bulbs coalescing into the superior turbinate 
 
Right  superior 
turbinate 
Right middle 
turbinate
Right inferior
turbinate
 
 
 
 
Olfactory Cortex 
 
The olfactory lobe or cortex (brodman area 34) in the human is a rudimentary elongated 
structure and lies beneath the frontal lobe and is bordered laterally by the temporal lobe and 
indents the underlying frontal lobe by the formation of a sulcus 
(39)
. 
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The Mitral cell axons project to the olfactory cortex via the olfactory tract. The anterior 
olfactory nucleus (AON) is the first structure to receive projections from the olfactory bulb 
via the lateral olfactory tract. The AON plays an important role in the perception of odorants 
and is often thought to represent the anterior olfactory cortex which then relays connections 
onto the primary olfactory cortex in the medial temporal lobe and the secondary olfactory 
cortex in the orbitofrontal cortex, with some fibres crossing over to the contralateral side 
(39)
.  
 
The primary olfactory cortex includes the piriform cortex as well as the olfactory tract, the 
uncus of the hippocampus, and the anterior part of the parahippocampal gyrus. The 
enterorhinal area or secondary olfactory cortex connects to the thalamus, basal forebrain and 
the limbic system 
(39)
. The priform cortex is involved with odour recognition and the 
entorhinal area more associated with memory and smell associations. The thalamus is thought 
to be involved in the conscious level of smell perception whereas the amygdale and 
entorhinal areas represent the limbic system and the subconscious perception. The olfactory 
system is the only sensory system that has direct cortical projections without a thalamic relay 
nucleus 
(39;62)
.  
 
 
 
Perception of Nasal Airflow 
 
One of the five functions of the nose is nasal breathing, as well as olfaction, humidification, 
filtration and warming. The perception of nasal breathing or airflow is mediated and 
controlled through the somatosensory afferents of the trigeminal nerve. This feedback process 
ensures optimal nasal patency, although can remain disordered even in the presence of a 
patent airway. The majority of the inspired nasal airflow runs inferiorly along the nasal cavity 
and the percentage of airflow directed to the olfactory region with each breath under resting 
conditions is about 10% 
(63)
. Sniffing increases the percentage of inspired air at the olfactory 
area to 20% (250 ml) making the perception of smell more appreciable 
(64)
. 
 
The complaint of nasal airflow blockage correlates poorly with objective findings and 
remains a challenge to  rhinologists 
(65)
.  Patients with large, typically post operative nasal 
cavities still perceive the sensation of nasal blockage 
(64)
. Nasal airflow during normal nasal 
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breathing passes through the external nasal valve in a laminar flow pattern and its velocity is 
approximately 2-3m/s. The air then passes through the internal nasal valve, the narrowest part 
of the nasal cavity, and speeds up significantly to 12-18m/s. The air stream then becomes 
more turbulent as it then flows into the nasal vault owing to the larger cross sectional area 
and its speed reduces to 2-4 m/s 
(63)
. Turbulence is a precondition for gaseous interaction 
between the air and mucosa which is vital for warming, humidification, filtration and 
olfaction. The middle turbinate then acts as an air foil enabling a change in direction of 
airflow and splits the airstream so as to waft superiorly into the olfactory cleft 
(63)
. 
 
The nasal mucosa as well as being lined by respiratory mucosa also consists of a vast network 
of erectile vascular tissue containing arterioles, arteriovenous anastomosis and venous 
sinusoids which enables the controlled process of engorgement. The process of congestion is 
under humerol and senserineural control and ensures optimal resistance and the ideal 
turbulent airflow. The nasal cycle is a physiological phenomenon whereby the left and right 
nasal cavities alternate in nasal congestion whereby the resistance is increased on one side 
and decreased on the other. The “intrinsic nasal cycle” is present in about 80% normal 
individuals, wherein only one nostril remains fully patent at one time. It usually lasts 2-6 
hours and alternates between the nostrils. The overall resistance remains the same. This 
process was first described by Kayser in 1895. Sweat and lacrimal secretions are involved in 
chemosignalling which incur both behavioural and hormonal change in others; including 
menstrual synchrony and the smell of both fear and empathy 
(63)
. 
 
 
An odorant may reach the olfactory mucosa through 2 different routes; sniffing through the 
nose (orthonasal) and via the mouth (retronasal). The latter process facilitates the flavours of 
foods and has been shown through functional MRI to be processed differently within the 
olfactory cortex The nose provides 2 different olfactory inputs to the brain one from each 
nostril and although not truly understood this dual process is thought to play a role in 
localization of smells with the ability to find food 
(66)
. 
 
Objective Measurement of olfactory activity 
 
An electro-olfactogram (EOG) measures the action potential activity of olfactory receptor 
neurons (ORNs) by electrode placement on the olfactory mucosa 
(44;62;67)
. However, olfactory 
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event related potentials are now universally used which are measured via electrode placement 
on the scalp following an odorant stimulation. The olfactory event-related potentials 
(OERPS) are specific electroencephalography (EEG) recordings triggered by an odorant 
stimulant. The odorant is introduced via an olfactometer which enables repeatable and 
calibrated odorant delivery. In anosmic patients they are absent and in hyposmic patients they 
are present in approximately one third of patients and therefore require additional 
psychophysical olfactory measurements including Sniffin sticks or UPSIT tests 
(68)
. OERPs 
play a role in predicting olfactory recovery following a viral infection and if found early in 
the recovery process convey a positive predictor for a favourable outcome 
(69)
. Event related 
functional MRI equally measures objectively olfaction by mapping out cerebral activity 
following an olfactory stimulant and has been used in determining olfactory cerebral 
pathways 
(70)
.  
 
 
Objective nasal airflow measurements 
 
Rhinomanometry is the objective measurement of nasal resistance and is calculated by 
measuring air flow and pressure within the nose and extrapolating the respective resistance. 
The internal nasal valve area can be measured using acoustic rhinometry which measures the 
cross sectional area of the nasal cavity as a function of longitudinal distance along the floor of 
the nasal cavity. The nasal cavity is divided into anterior, middle and posterior segments. The 
anterior segment which is the first 3 cms of the nasal cavity corresponds to the nasal vestibule 
and internal nasal valve and contains only very limited congestive capacity otherwise known 
as the minimal cross sectional area 1 (MCA 1) whereas the middle third which measures 
from 3cms to 5.2cms or MCA 2 contains the inferior and middle turbinate areas and 
represents the main congestive area 
(51)
. 
 
 Olfactory dysfunction 
 
Definition of Anosmia 
Anosmia is the inability to smell, hyposmia is the reduced ability to smell and normosmia is 
the normal ability to smell.  Parosmia is the distorted ability to smell and Phantosmia is the 
ability to smell in the absence of an odorant. Physiological anosmia occurs as a result of 
odorant saturation during prolonged smelling of a high intensity odorant such as vanillin for 
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more than 15 minutes. The ORN binding receptors become saturated and this phenomenon is 
reversible 
(48)
. 
 
Aetiology 
Olfactory dysfunction is frequent and can profoundly influence a patient’s quality of life.  
Olfactory dysfunction has been reported to affect approximately 5% of the UK population 
with a prevalence of over 25% in other published population studies 
(49)
. As a sensory 
disorder it is more common than blindness and deafness and carries significant psychosocial 
consequences for the sufferer 
(71;72)
. Hyposmia is present in 16% of the population and rates 
are significantly higher in patients with rhinological disease 
(73)
. It rarely presents itself in 
isolation or in the absence of trauma, but usually with other symptoms of nasal pathology 
including nasal obstruction and rhinorrhoea.   
 
Anosmia is a recognized symptom which helps qualify the diagnosis of chronic rhinosinusitis 
according to the EPOS guidelines 
(74)
. Studies have also shown that olfactory dysfunction 
affects over 50% of the population older than 65 years 
(75).
  Philpott et al, demonstrated that 
55% of patients who complained of hyposmia had low combined olfactory test (COT) scores 
whereas 33% of patients with a low COT score had no subjective hyposmia 
(76)
.  
 
Pathogenesis of Anosmia 
The commonest causes for anosmia are head injury, viral upper respiratory tract infection  
and CRS and they can account for up to 80% of presentations 
(49;77)
. Olfactory disorders can 
be classified as conductive, sensory or neural disorders 
(78)
. Conductive disorders reflect 
diminished access of odorants to the olfactory neuroepithelium. Sensory disorders on the 
other hand, involve direct damage to the neuroepithelium and neuronal disorders reflect 
injury to the olfactory bulb and central olfactory pathways 
 
Treatment of Anosmia 
Hyposmia caused by CRS is thought to be the most amenable to therapeutic interventions. 
Most hyposmic patients are thought to suffer with allergic rhinitis, chronic rhinosinusitis or 
nasal polyposis. The mainstay of treatment for this group is intranasal/topical corticosteroids 
(79-81)
. Bugten et al, showed that patients with CRSwNP complain more of nasal blockage and 
a reduced sense of smell whereas patients with CRSsNP complain more of facial pain and 
headaches, interestingly they did not find a significant difference in subjective symptom 
 35 
 
improvement, with both groups responding similarly following FESS 
(82)
. 
 
The role of FESS in CRS 
The role of FESS in sinonasal disease is well documented and according the EPOS guidelines 
is indicated when medical treatment fails. Its main objective is to reduce nasal obstruction 
and to enable ease of passage of topical steroids into the sinonasal openings. The evidence 
supporting the efficacy of FESS in the treatment of CRS with or without polyps shows it to 
be as effective as medical treatment, but not better 
(74;83)
. 
Medical Treatment 
Studies have shown that steroids either in the form of a nasal spray or drops are effective in 
treating hyposmic patients with concurrent nasal disease. Golding-Wood et al showed that 
using topical steroids (bethamethasome) daily for six weeks improved the UPSIT test scores 
significantly in their small hyposmic cohort and suggesting that topical steroid therapy is 
effective in treating perennial rhinitis and nasal polyps who also suffer with hyposmia 
(84)
. A 
study by Chalton et al, found that the distribution of the steroidal drops are enhanced when 
taken in the 'head down' or Moffats position and is believed to encourage maximum exposure 
of the drug to the nasal and paranasal sinus mucosa 
(85)
. A study by Mott et al demonstrated a 
significant improvement in subjective and objective olfactory scores following topical nasal 
steroid spray in the head down position after 8-26 weeks treatment 
(86)
. Studies evaluating the 
effects of antibiotics and long term macrolides in the treatment of CRS and potentially 
olfaction are equivocal
(87)
. Systemic corticosteroids have been shown to significantly improve 
hyposmia in patients with underlying sinonasal disease. Interestingly in the same study 
systemic steroids did not improve anosmia secondary to a viral insult suggesting a permanent 
damage to the olfactory mucosa 
(88)
.   
Alternative Therapies 
Alternative therapies such as herbal remedies, vitamin A, trace elements such as magnesium 
and zinc have been advocated by some studies and noted no improvement in olfactory 
function when zinc supplements were given to subjects 
(81;89)
. 
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Head Injury 
Patients with head injuries are the second largest group referred and account for 20% of 
anosmic patients seen in the out-patients. At present there does not exist a specific treatment 
for this group of patients.  Studies have shown that a third of patients recover spontaneously 
which is thought to be due to regeneration of the olfactory system 
(90)
. It has been shown that 
complete recovery can take up to five years 
(90)
. Rombaux  et al showed that post-traumatic 
recovery of olfaction is highest in the first 6 months but continues for up to 2 years in 
addition demonstrating that an olfactory bulb volume of greater than 40mm correlated 
positively with recovery of sense of smell 
(91)
. 
 
 
Post viral 
The third largest groups of patients are those with anosmia following an upper respiratory 
tract infection. They account for about for 15% of referrals. Equally there is not an effective 
medical treatment to restore the olfaction function in this group of patients 
(92)
. Recovery 
occurs spontaneously in 50% of patients and occurs commonly six months after onset and the 
duration of recovery can be as long as 3 years
(79)
. Patients with anosmia for more than a year 
have been shown to have a poor prognosis in terms of recovery 
(93)
. 
Role of FESS in Olfactory dysfunction 
Current evidence supports the efficacy of  endoscopic sinus surgery in the significant 
improvement of olfactory dysfunction in CRS patients both in the short and long term and up 
to 5 years post operatively 
(94)
. Additional studies have also shown improved olfactory 
outcomes following endoscopic sinus surgery albeit not always significant 
(77;95)
. CRS sub 
group analysis of olfactory outcomes using psychophysical measurements in patients with 
CRSwNP and CRSsNP have been limited in numbers with regards to separate analysis for 
quality of life outcomes, olfactory function and other PROMs, however, a recent study 
evaluating CRS sub group analysis following endoscopic sinus surgery demonstrated a 
significant olfactory improvement in the CRSwNP sub group as measured by Sniffin sticks. 
This significant improvement was not demonstrated in the CRSsNP subgroup, although as a 
whole the general CRS population improved significantly 
(96)
. Interestingly this olfactory 
outcome has not been evaluated using the UPSIT psychophysical olfactory measuring 
technique.  
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One of the earliest studies to assess olfaction following nasal surgery was performed by 
Kimmelman in 1994 
(97)
. This study included 93 patients undergoing all types of nasal 
surgery; septal and turbinate surgery, rhinoplasty surgery, intranasal polypectomy and   sinus 
surgery. The ‘University of Pennsylvania Smell Identification Test’ (UPSIT) was used and 
found 66% of patients either improved their sense of smell or remained unchanged following 
surgery. The remaining 34% showed a decline in olfaction with one patient becoming 
anosmic. This study forms the basis of the commonly quoted 1% risk of anosmia with nasal 
surgery. The cause for this anosmia remains unknown and may be due to anatomical 
alteration following surgery or chemosensory damage following the introduction of nasal 
medication. Lund and Scadding demonstrated a significant improvement in olfaction 
following FESS in a cohort of 200 patients 
(98)
.   
 
Rowe-Jones et al, performed a 5 year prospective study on 109 post FESS CRS patients of 
which 75% were CRS with polyps and a significant improvement of olfaction was shown at 2 
years post surgery which became non significant at 5 years 
(99)
. Jiang et al, measured 
olfaction using the UPSIT test, single threshold test and the discrimination test on 75 FESS 
patients and found irrespective of the type of olfactory test performed there was not a 
significant improvement 
(100)
.  
 
Olfactory prognostic factors in efficacy of ESS 
 
In a cohort of 330 CRS patients with olfactory dysfunction increasing age, nasal polyposis, 
smoking status and asthma were significant predictor factors for olfactory dysfunction 
whereas previous ESS or allergic rhinitis were not and equally septal deviation or inferior 
turbinate hypertrophy 
(101)
. Rudmik and Smith performed a literature review on the efficacy 
of FESS in CRS related olfactory dysfunction. It was concluded the evidence supporting its 
efficacy is equivocal and not significant. It was very difficult to predict olfactory outcomes 
following surgery and although a positive affect was more likely to occur, patients still 
remained hyposmic and there were some studies showing no change. It was extrapolated that 
patients who were hyposmic and had CRS with polyps stood the best chance of improvement 
and hence were good predictive factors 
(102)
. 
 
A recent study by Shriever et al in 2013 looked at the effects of nasal surgery including both 
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sinus surgery and septal surgery on olfaction using the 16 item odor identification sniffin 
stick test. At 3.5 months post operatively there was a significant improvement in the sinus 
surgery arm as opposed to a non significant improvement in the septal surgery arm and 
interestingly they both became non significant at 12 months. They also found that polyps and 
eosinophilia were good prognostic factors for a significantly improved olfactory outcome. 
Conversely, in the non polyp sinus group the improvement was not significant 
(103)
. The 
effects of FESS and septal surgery on olfactory function are summarised in table 1. 
 
 
Table 1 Effect of FESS and Septal Surgery on Olfactory function 
 
Author Number of patients Outcome 
 
Kimmelman, 1994 93 patients including septal and 
sinus surgery 
66% Improved 
34% declined 
1% Anosmia 
Lund and Scadding, 1994 200 FESS patients Significantimprovement in olfaction 
following surgery 
Rowe-Jones et al, 2005 109 FESS patients (75% 
polyps) 
Significant olfactory improvement at 2 
years and became non-significant at 5 
years 
Jiang et al, 2008 75 FESS patients Non significant improvement in 
olfaction 
Lind H et al, 2016 97 FESS patients Significant improvement in the 
CRSwNP subgroup, and although 
improvement in the CRSsNP group 
was demonstrated it was non 
significant 
Schriever et al 2013 157 FESS and septal surgery 
patients 
Significant improvement in olfactory 
improvement at 3.5 months and non 
significant, but still improved at 12 
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months. 
CRSwNP a good prognostic factor, 
unlike CRSsNP 
Pade et al 2008 150 septal surgery patients 13% improvement only 
81% no change 
6% decrease 
Randhawa et al 2016 43 functional Septorhinoplasty 
patients 
A significant improvement in olfaction 
was demonstrated  
Damm et al 2003 30 patients undergoing 
septoplasty and inferior 
turbinate surgery 
80% had improved olfactory outcomes 
Pfarr et al 2004 30 patients undergoing 
septoplasty surgery 
No significant improvement in 
olfaction was seen 
 
 
 
NOSE score in the FESS population 
Up to now, the NOSE score which is a patient reported outcome measure (PROM) commonly 
used in septoplasty and septorhinoplasty surgery, has not been evaluated in the CRS 
population even though it has been recommended in CRS patients 
(65;104)
. CRS studies have 
demonstrated that nasal blockage VAS scores following ESS improve significantly and 
correlate with improved olfactory function on sniffin stick evaluation 
(105)
. The question 
remains whether a specific PROM looking at all aspects of nasal blockage (NOSE) equally 
improves following ESS and also correlates with improved olfactory function. Our aims were 
to determine the efficacy of endoscopic sinus surgery (ESS) on olfactory function in 
CRSwNP and CRSsNP sub groups and to further evaluate the nasal obstruction and symptom 
evaluation (NOSE) scale in the CRS population. 
 
 
Septorhinoplasty surgery and sense of smell 
The role of septorhinoplasty surgery in the treatment of olfactory disorders remains equally 
equivocal. In the majority of patients the sensorineural component of the olfactory pathway is 
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intact unlike in the CRS group and the conductive pathway is obstructed either through a 
deviated septum or reduced internal and external valve function 
(106)
. Transient post-operative 
hyposmia is a common feature following external SRP and can require 6 weeks to 6 months 
for recovery to pre-operative olfactory function 
(107)
 . The impact of surgery upon olfactory 
function can also be effectively assessed using pre- and post-operative sinonasal outcome test 
(SNOT-22) scores. In this study olfaction as measured subjectively by the SNOT-22 
improved significantly following Septorhinoplasty surgery 
(108)
.  
 
In a prospective study of 150 patients undergoing septal surgery, Pade et al assessed olfaction 
using ‘Sniffin’ Sticks’, and demonstrated a 13% improvement, no change in 81%, and a 
decreased olfactory function in 7% 
(109)
. Shriever et al demonstrated in the septal arm after a 
long term follow up of 44 patients that a significant change in olfaction was not seen
(103)
 . 
Damm et al, demonstrated that septoplasty and inferior turbinectomy caused a profound 
increase in supra-threshold odour identification, but not an increase in odour thresholds
(110)
.  
Interestingly, Pfaar et al, showed a contradictory result in their cohort of 25 patients whereby 
the supra-threshold odour identification did not improve but the odour threshold did 
(111)
. In 
summary, with the available data available, there is a likelihood of improvement in the sense 
of smell following septorhinoplasty surgery. 
 
Lateralised olfactory function or unilateral anosmia exists in 15% of healthy people 
(112)
.  A 
deviated septum has also been shown to reduce air entry and cause nasal obstruction but has 
also been shown to reduce olfactory function with a subsequent reduction in the size of the 
olfactory bulb 
(113)
. Fyrampas et al demonstrated that patients with a nasal septal deviation 
showed higher olfactory thresholds on the convex side and the post operative scores 
following septoplasty surgery did not show a convincing increase in olfaction 
(114)
. Randhawa 
et al demonstrated a statistically significant improvement in Sniffin stick olfactory 
identification following functional septorhinoplasty surgery 
(126)
. 
 
It is difficult to differentiate whether hyposmia is due to a conductive or sensorineural cause 
although in septorhinoplasty surgery the olfactory sensory component is more than likely to 
be functioning particularly on comparison with CRS patients. A case report describes the 
complete restoration of olfaction following a functional septorhinoplasty procedure prior to 
which the patient was anosmic. Hypothetically the olfactory regeneration may have been 
reinvigorated through repositioning the perpendicular plate as shown in figure 7 which is in 
 41 
 
continuity with the crista galla and hence potentially stimulating the regeneration of the 
olfactory neurons 
(115)
.  
 
 
 
Figure 7 
The perpendicular plate and crista galli are in continuum and represent the area of transit for 
the olfactory bundles into the anterior skull base 
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Hypotheses and aims 
The primary hypothesis states that olfactory harvesting is a patient safe procedure and does 
not incur an increase in complication rate and does not reduce  nasal function including the 
sense of smell when compared to a control group. The secondary hypothesis states that ESS 
improves the olfactory outcome in CRS patients both with nasal polyps (CRSwNP) and CRS 
without nasal polyps (CRSsNP).  
 
The additional aims of this thesis are to perform a subgroup analysis within the CRS cohort 
and determine whether there is a statistical significant difference in olfactory outcomes 
between CRS patients with nasal polyps (CRSwNP) and CRS without nasal polyps 
(CRSsNP) and also critique the effectiveness of the nasal obstruction symptom evaluation 
(NOSE) patient reported outcome measure (PROM) in the CRS population which has not 
been previously assessed. Overall, the aim is to better understand the effects of nasal 
olfactory biopsy surgery on olfaction as well as patient morbidity and secondly understand 
the effects of sinus surgery on olfactory function in the CRS subgroups whilst additionally 
evaluating the NOSE PROM.  
 
The primary endpoint measure will be olfaction. This will be measured using the University 
of Pennsylvania Smell Identification Test (UPSIT). The secondary nasal function endpoints 
will be surgeon reported endoscopic outcomes (Lund-Kennedy Staging System), and patient 
reported  quality of life (QOL) and symptom outcome measures including; Sino-Nasal 
Outcome test 22 (SNOT 22) , Visual Analogue Scale (VAS) of nasal symptoms  and the 
Nasal Obstruction and Symptom Evaluation scale (NOSE).This research is being undertaken 
in connection with our work on OEC culture techniques, with a view to perform clinical trials 
of nerve repair in the future 
(4;23)
. 
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CHAPTER 2 
MATERIALS AND METHODS   
 
Ethical Approval 
Full Ethical and Research and Development (R&D) approval was sought by PA as the 
principal investigator for the RNTNEH arm of this trial following original approval by DC at 
the National Hospital for Neurology and Neurosurgery and Institute of Neurology joint 
research ethics committee. REC reference: 05/Q0512/103 
 
Informed Consent 
Patients were consented for participating in this study separately to their consent for the 
operation. The research consent form and patient information sheet were explained to the 
patient both by the Principal Investigator and research nurse. The aims of the study, risk 
factors of the procedure and the absence of direct benefit to the patients themselves were 
discussed prior to obtaining their consent. The risks of CSF leak and orbital damage were 
also outlined during consent and remedy surgery fully described. The patients were allowed 
24 hours to reflect and reconsider. The consent form and patient information sheet were 
formulated and developed through  utilizing Patient Public Involvement strategies as well as 
‘patient forum groups’ based both at the National Hospital for Neurosurgery and Neurology 
and Royal National Throat Nose and Ear Hospital, Copies of the aforementioned  forms  are 
enclosed in the appendix. 
 
Patient Recruitment 
 
The 131 patients enrolled in this study were recruited from PA’s Rhinology clinic at the 
Royal National Throat Nose and Ear Hospital over a 2 year period. Those requiring 
Functional Endoscopic Sinus Surgery (FESS) for the treatment of a broad range of sinuse 
diseases as well as neoplasia were invited to participate in this prospective study. The 
exclusion criteria included patients aged under the age of 16, pregnancy and the inability to 
comprehend the assessment questionnaires. 
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Table 2 Population data  
 
Patients Data 
Demographic 
Data 
Total, No 131 
Age, mean ( sd), yr 47.0 ( 15.2) 
Sex, No (%) 54 ♀ (41.2%) 
77 ♂ (58.8%) 
Surgical 
indication 
CRSwNP with Polyps, No (%) 
CRSsNP, without Polyps No (%) 
Antro-choanal Polyp, No (%) 
Inverted papilloma 
Foreign body, No (%) 
Fungocele / Mucocele, No (%) 
Spheno-palatine ligation, No (%) 
Amyloidosis, No (%) 
Sarcoidosis, No (%) 
Ethmoidal adenocarcinoma, No (%) 
Maxillary hypoplasia, No (%) 
Oro-antral fistula, No (%) 
Infected Concha bullosa, No (%) 
CSF leak, No (%) 
Sphenoid fungus ball 
Pott's puffy tumour 
Frontal sinus stenosis 
55 (42.0%) 
42 (32.1%) 
9 (6.9%) 
7 (5.3%) 
4 (3.1%) 
3 (2.3%) 
1 (1%) 
1 (1%) 
1 (1%) 
1 (1%) 
1 (1%) 
1 (1%) 
1 (1%) 
1 (1%) 
1 (1%) 
1 (1%) 
1 (1%) 
Comorbidities Revision surgery, No (%) 
Smoking, No (%) 
16 (12.2%) 
26 (19.8%) 
CT-scan Lund-Mackay score, mean ( sd)  10.7 ( 6.9) 
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The patients recruited for this thesis reflect the tertiary referral nature of PA’s clinic with 
approximately 75% of the patients suffering with CRS as outlined in Table 2. The CRS 
patients described a combination of symptoms including nasal obstruction, reduction in their 
sense of smell, rhinorrhoea and pressure like facial pain. The cause for the CRS ranged from 
inflammatory nasal polyposis, viral, bacterial or fungal rhinosinusitis. We also recruited non-
CRS patients with structural disorders as well as patients with benign and malignant tumours. 
The biopsies from the patients with neoplasia were harvested from the normal side.  
 
The EPOS guidelines were adhered to prior to listing of patients for sinus surgery and the 
majority of our patients suffered with refractory chronic rhinosinusitis 
(74)
. EPOS guidelines 
define rhinosinusitis (including nasal polyps) as inflammation of the nose and the paranasal 
sinuses characterized by two or more symptoms, one of which should be either nasal 
blockage/obstruction/congestion or nasal  discharge (anterior/posterior nasal drip): +/- facial 
pain/pressure, +/- reduction or loss of smell; and either endoscopic signs of polyps and/or; 
mucopurulent discharge primarily from the middle meatus and/or CT changes of mucosal 
changes within the ostiomeatal complex and/or sinuses. The aim of Endoscopic Sinus 
Surgery (ESS) is to improve the ventilation of the sinuses with restoration of mucociliary 
clearance and enhancement of medical treatment. 
 
Patients Preoperative and Post Operative symptom Assessments 
 
Patients were evaluated pre operatively, intra operatively and post operatively both in the 
immediate post operative recovery and subsequent post operative follow-up at 6 months. We 
compared our findings with a control group who equally underwent FESS surgery but 
without an olfactory biopsy. The patient’s medical history was documented including age, 
sex, presenting complaint, past medical and surgical history, drug history, allergies and 
smoking status.  In addition, recent use of topical and/or oral steroids was documented.  
 
The subjective patient reported outcome measurements (PROMs) used in this study included 
the SNOT 22 quality of life score, the NOSE score and VAS scores. Disease severity was 
also objectively assessed on CT scanning which was a surgical prerequisite. Disease severity 
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was graded according to opacification on CT scanning using the Lund and Mackay grading 
system. Disease severity was also assessed using the Lund-Kennedy surgeon reported 
outcome measure which grades nasal mucosa quality and the sense of smell was measured 
pre and post operatively using the UPSIT.  
 
Post Operative morbidity 
 It was important to both patient and surgeon reported outcomes measures and although other 
olfactory measurements and nasal function PROMs could have been used in this study, we 
decided to focus on those we are more familiar with as well as their subsequent interpretation. 
The individual PROMs and surgeon reported outcome measures used in this study will be 
critiqued within the discussion. 
 
 
Patient Safety was assessed through the evaluation of both intra operative and post operative 
complication rates which included bleeding rates, infection and CSF leakage. The immediate 
adverse safety outcomes evaluated during the biopsy were haemorrhage and cerebrospinal 
fluid leakage. This was assessed at the time of surgery and immediately post-operatively. 
Secondary haemorrhage and infection was assessed at the 3 week follow up appointment. 
 
Radiology 
The Lund and Mackay staging system scores severity of sinus opacification found on CT 
scanning 
(116)
. The staging system bilaterally scores the five sinuses from zero to two, 
depending on severity of opacification. A zero is assigned to a sinus without opacification 
and a two is assigned to complete opacification, and a one for partial opacification. The 
ostiomeatal complex (OMC) is also scored but either one or two (presence or absence of 
opacification). The grading score ranges from 0 to 24. Both CT and MRI images of the 
paranasal sinuses are depicted in figures 8, 9 and 10. 
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Figure 8 
Coronal CT scan of paranasal sinuses showing partial opacification of the anterior ethmoidal 
sinuses and highlighting the inferior, middle and superior turbinates 
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Figure 9 
A normal coronal CT scan of the sinuses highlighting the right superior turbinate 
 
 
 
Figure 10 
T1 MRI scan highlighting the superior turbinates and their attachments to the anterior surface 
of the sphenoid sinuses 
Superior 
turbinate
Right 
sphenoid 
sinus
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Lund and Kennedy Surgeon reported sinus outcome 
 
The Lund-Kennedy endoscopic scoring system is a clinician reported outcome measure 
which is subjectively scored by the surgeon and quantifies the pathological state of the 
paranasal sinuses and in doing so quantifies the severity of polyps, discharge, edema, 
scarring, or adhesions and crusting and the score ranges from 0 to 20. Polyps are graded as 
absent (0), present in the middle meatus (1), or present beyond the middle meatus (2). 
Discharge is graded as not present (0), thin (1), or thick and purulent (2). Edema, scarring, 
and crusting are each graded as absent (0), mild (1), or severe (2) 
(117-119)
. The appearance of 
normal sinonasal mucosa is depicted in figure 11. 
 
 
 
Figure 11 
Endoscopic photograph of the right nasal cavity, showing the right middle turbinate, middle 
meatus and exhibiting a normal appearance. 
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Visual Analogue Scale 
This is a validated subjective scoring system used for discreet individual symptom scoring. 
The patient marks on a line from zero to ten their perceived severity and a scale of five has 
been shown to affect the quality of life of the patient. Visual analogue scales for smell and 
overall nasal symptoms were completed on a scale of 0-10 in terms of severity. 
 
Sino-Nasal Outcome Test (SNOT22) 
The SNOT-22 is a validated 22 question quality of life disease specific questionnaire which 
rates the severity of their symptoms from 0 (no problem) to 5 (problem as bad as it can be) 
and gives a theoretical total score of 110 (Figure 12) 
(120)
 .  
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Figure 12 SNOT 22 Questionnaire 
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Nose Questionnaire 
The nasal obstruction symptom evaluation (NOSE)  questionnaire, as shown in figure 13, is a 
validated disease-specific instrument which assesses different components of nasal 
obstruction 
(104)
.  It is commonly used in otolaryngology practices to provide an objective 
measure of nasal obstruction.  The instrument is brief and easy to complete, with minimal 
respondent burden.  It consists of 5 questions seeking to rate the burden of nasal obstruction 
during the past month scored from 0 (not a problem) to 4 (severe problem) giving a score of 
between 0-20. It is well validated and has been used to measure quality of life improvements 
in nasal septal surgery, functional septorhinoplasty and nasal valve surgery with good effect. 
Classically the final result is multiplied by five to give a maximum score of 100.  
 
 
 
 
Figure 13 
 Nose questionnaire 
 
 
 
 53 
 
UPSIT 
The UPSIT is our screening test of choice and works on the scratch and sniff principle 
revolving around 40 different odors, as shown in figure 14. It tests cognition at the same time. 
The UPSIT test has been proven both reliable and reproducible as a simple clinical test of 
olfaction and is the most commonly used test. The raw UPSIT scores were calculated as the 
number of correct identifications, ranging from 0 to 40, with 40 representing perfect olfaction 
(121)
.  
 
 
 
 
 
 
 
 
Figure 14 
UPSIT Questionnaire 
 
 
Surgical Procedure 
 The nose was prepared in the majority of cases with Moffatts solution (2mls of 6% cocaine, 
1ml of 1:1000epinephrine, 2mls of 8% sodium bicarbonate and made up to 10mls with 5mls 
of normal saline) and applied by the anaesthetist in the anaesthetic room prior to surgery. 
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Only very occasionally if the patient had cardiac morbidity was an alternative preparation 
used in the form of co-phenylcaine nasal spray (lignocaine hydrochloride 50mg/ml and 
phenylephrine hydrochloride 5mg/ml). The patients were positioned supine with a 20 degree 
head elevation using hypotensive general anaesthetic techniques. The nose was further 
decongested under endoscopic guidance by the surgeon through applying ribbon gauze 
soaked epinephrine (1 in 1000 epinephrine) into and around the middle meatus. 
The nasal cavity was simultaneously endoscopically assessed using a 4mm endoscope and 
undertaking the three pass technique and evaluated using the Lund Kennedy scoring system. 
The nasal mucosa was assessed and scored for oedema, discharge and polyposis as well as 
crusting and adhesions. 
. 
Topical adrenaline was further applied to the superior turbinate prior to the olfactory mucosa 
harvesting technique, following which the remaining endoscopic sinus surgery was 
completed. Post operative nasal packing was not used although  a half inch ribbon gauze 
soaked in1 in 1000 adrenaline was installed and removed in recovery before being transferred 
back to the ward. Patients were routinely discharged on the same day in the majority of cases.  
The harvesting procedure was performed using the standard FESS set which included 
endoscopic forceps and scissors as shown in figure 15. 
 
Figure 15 Selection of endoscopic instruments 
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The post operative nasal medications included regular nasal douches with salt and sodium 
bicarbonate and followed up in out-patients at 3 weeks to check histology and to 
endoscopically decrust as required. Patients were then seen at 6 months post operatively and 
further evaluated both endoscopically using decongestant in the form of co-phenylcaine nasal 
spray with repeat PROMS and smell evaluation. 
 
 
Statistics and sample size 
 
Statistical tests were undertaken using Stata version 13.1 (StatCorp, Tx). Graphical 
presentations were performed using GraphPad Prism 5.0a (GraphPad Software, San Diego, 
California, USA). 
 
The olfactory scores between groups were compared using 2-ways analysis of variance, with 
turbinate biopsy and endoscopic sinus surgery as a source of variation. Analysis was 
performed first on the raw UPSIT scores as the primary endpoint. Scores were also adjusted 
for age and gender using percentile norms published by Doty et al (121). 
 
The impact of secondary endpoints (Lund-Kennedy endoscopic outcome, SNOT-22, VAS, 
NOSE score) were also sought by 2-ways ANOVA. Correlation between objective olfactory 
score assessed by UPSIT and subjective patient’s perception assessed by visual analogue 
scale on sense of smell was analysed using Spearman regression. 
Effects of cofactors such as smoking, sex and polyposis on baseline UPSIT scores were 
analysed using U Mann Whitney test. Linear regression analysis was used to calculate the 
correlation between age and the baseline UPSIT score. Interaction of cofactors on the 
olfactory results of sinus surgery was evaluated using 2-ways ANOVA.  
 
 
Sample Size Calculation 
All patients were consented for the procedure and refusal for the biopsy allowed for potential 
entry into the control arm. Sample size calculation of 41 patients in each arm was deemed 
satisfactory so as to provide a significant result although a larger sample was deemed ideal to 
 56 
 
account for drop out. Using data from the pilot series of patients, 7 pre-op and 4 post-op 
UPSIT scores, average change in mean UPSIT is 0.33, sd 3.2, to detect a change difference in 
score change of 0.33 in control group and 3 in olfactory biopsy group, power 80%, P=0.05, 
requires 31 patients in pre-op and post-op groups. Allowing for 10 patients loss to follow-up, 
a sample size of 41 patients was required for each group. 
 
Estimated sample size for two-sample comparison of means; Test Ho: m1 = m2, where m1 is 
the mean in population 1 and m2 is the mean in population 2, assumptions: alpha =  0.0500  
(two-sided) power =  0.9000, m1 = .33, m2 = 3, sd1 = 3.2 and sd2 = 3.2, n2/n1 = 1.00 
and estimated required sample sizes: n1 = 31 and n2 = 31. 
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CHAPTER 3 
 
RESULTS 
 
 
Surgical modifications of the superior turbinate harvesting technique 
The preliminary findings of this harvesting technique have been published although the 
resultant modifications have not been documented 
(4)
. This technique has been modified so as 
to ensure minimal patient morbidity particularly with regards to anterior skull base injury and 
CSF leak as well as significant bleeding. During this modification process only one reported 
CSF leak was reported and was immediately apparent. The defect was subsequently repaired 
with a fat plug and a fascia lata with free mucosal graft reconstructive techniques. The patient 
made a full and beneficial recovery. In this particular case the superior portion of the superior 
turbinate was being trialed and it was immediately apparent the anterior skull base had been 
breached with an immediate CSF leak. As a result the superior section was abandoned and all 
subsequent biopsies included the middle portion of the superior turbinate. The superior 
section of the superior turbinate lies in close proximity to the skull base. 
 
The key with this biopsy technique is to include the whole of the middle section ensuring the 
turbinate bone remains in-situ so as to act as a scaffold and allow for orientation of the nasal 
mucosa. It became apparent during the modification phase of our harvesting technique that 
histological preparation of the biopsy was made easier when the mucosa was still attached 
and orientated onto the underlying turbinate bone and lamina propria. In figure 16 the left 
superior turbinate can be seen with the sphenoid ostium visualised medially and the 
procedure performed as outlined in figures 17 to 20 with image guidance as outlined in 
figures 21 to 31. 
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Figure 16 
Left superior turbinate can be seen with the patent sphenoid ostium visualised medially 
adjacent to the septum on the left 
 
 
 
Figure 17  
Endoscopic micro scissors are shown making the superior horizontal incision. 
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Figure 18 
Inferior horizontal incision to the superior turbinate is fashioned 
 
Figure 19 
The inferior incision is joined vertically to the superior horizontal incision and the middle 
section is removed gently with a blakesley forceps 
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Figure 20 
Middle section excised and sphenoid ostium visualised 
 
 
 
 
 
 
Image Guidance Delineation of skull Base 
 The anterior skull base was delineated during this process using intra operative image 
guidance which enabled accurate visualization of the superior turbinate and its skull base 
attachment. The superior nasal cavity starts anteriorly underneath the nasal and frontal bones 
as shown in figure 21 and progresses onto the skull base more posteriorly as highlighted in 
figure 22. The root of the right middle turbinate can just been seen in the bottom right of the 
figure. In figure 23 the root of the right middle turbinate is visualized and its image guidance 
image is superimposed on figure 24 showing its close proximity to the anterior skull base. 
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Figure 21 
Roof of nasal cavity underneath the nasal bones 
 
 
 
 
Figure 22 
Olfactory niche and the demarcation between under surface of nasal bones and skull base. 
The septum is medial and the middle turbinate lateral. 
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Figure 23 
Imaging guidance probe on root of middle turbinate 
 
 
 
 
Figure 24 
Superimposed image guidance view of skull base and the root of the middle turbinate 
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Figure 25 
Endoscopic view of the right superior turbinate 
 
 
 
 
 
 
 
 
In figure 25, the superior turbinate is seen in the background. In figure 26 the middle section 
of the superior turbinate is probed and super imposed with image guidance navigation which 
highlights its relationship with the skull base and sphenoid sinus 
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Figure 26 
Superimposed Image guidance navigation of the superior turbinate as shown in figure 24 and 
its relationship with the skull base. 
Superior turbinate 
attachment
Probe
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Figure 27 
Image guidance probe sited on the entrance of the right frontal sinus 
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Figure 28 
Super-imposed Image guidance navigation image from figure 27 of the right frontal sinus.  
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Figure 29 
Endoscopic image of the left superior turbinate as seen from the right nasal passage following 
the removal of posterior septum (septectomy) 
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Figure 30 
Endoscopic image of the right ethmoidal nerve just anterior to the olfactory prominence and 
posterior to the frontal sinus ostium 
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Figure 31 
Superimposed image guidance view of figure 30 
 
 
 
 
Image guidance 
The first olfactory nerve innervates the olfactory mucosa of the superior septum. It also 
demarcates the anterior boundary of the anterior skull base and therefore an important 
surgical landmark which is commonly used during the endoscopic modified Lothrop 
procedure or Draf 3 technique 
(57)
.The anterior ethmoidal sensory nerve is often seen before 
the first olfactory nerve and lies just anterior to the skull base as shown in figure 30. 
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Table 3 Comparison of the Population with and without Sup’ turbinate biopsy 
 
Patients Data Biopsy No biopsy 
Demographic 
data 
Total, No 65 66 
Age, mean ( sd), yr 47.2 (14.5) 46.7 (15.9) 
Sex, No (%) 24 ♀ (36.9%) 
41 ♂ (63.1%) 
30 ♀ (45.4%) 
36 ♂ (54.6%) 
Surgical 
indication 
CRS with Polyps, No (%) 
CRSsP, No (%) 
Antro-choanal Polyp, No (%) 
Inverted papilloma 
Foreign body, No (%) 
Fungocele / Mucocele, No (%) 
Spheno-palatine ligation, No (%) 
Amyloidosis, No (%) 
Sarcoidosis, No (%) 
Ethmoidal adenocarcinoma, No (%) 
Maxillary hypoplasia, No (%) 
Oro-antral fistula, No (%) 
Infected Concha bullosa, No (%) 
CSF leak, No (%) 
Sphenoid fungus ball 
Pott's puffy tumour 
Frontal sinus stenosis 
23 (35.4%) 
21 (32.3%) 
6 (9.2%) 
5 (7.7%) 
3 (4.6%) 
2 (3.1%) 
0 (0.0%) 
1 (1.5%) 
0 (0.0%) 
1 (1.5%) 
0 (0.0%) 
0 (0.0%) 
1 (1.5%) 
0 (0.0%) 
0 (0.0%) 
1 (1.5%) 
1 (1.5%) 
32 (48.5%) 
21 (31.8%) 
3 (4.5%) 
2 (3.0%) 
1 (1.5%) 
1 (1.5%) 
1 (1.5%) 
0 (0.0%) 
1 (1.5%) 
0 (0.0%) 
1 (1.5%) 
1 (1.5%) 
0 (0.0%) 
1 (1.5%) 
1 (1.5%) 
0 (0.0%) 
0 (0.0%) 
Comorbidities Revision surgery, No (%) 
Smoking, No (%) 
8 (12.3%) 
16 (24.6%) 
8 (12.1%) 
10 (15.2%) 
CT-scan Lund-Mackay score, mean ( sd)  9.7 (6.7) 11.8 (6.9) 
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Table 4 Outcome data 
 
 
Surgical Response pre-operative post-
operative 
p 
UPSIT 
(value) 
Whole population, mean ( sd) 
Superior turbinate biopsy 
No biospy 
25.9 (9.6) 
26.6 (9.3) 
25.2 (9.9) 
26.7 (9.7) 
27.9 (8.8) 
25.1 (10.7) 
0.3 ns 
0.2 ns 
0.9 ns 
UPSIT 
(percentile) 
Whole population, mean ( sd) 
Superior turbinate biopsy 
No biospy 
17.5 (23.3) 
17.0 (19.4) 
18.0 (26.9) 
19.4 (22.3) 
20.1 (21.6) 
18.8 (22.7) 
0.3 ns 
0.5 ns 
1.0 ns 
SNOT-22 
score 
Whole population, mean ( sd) 
Superior turbinate biopsy 
No biopsy 
51.9 (25.4) 
54.8 (24.5) 
48.9 (26.2) 
29.1 (24.2) 
32.7 (26.9) 
25.1 (20.3) 
<0.0001 *** 
<0.0001 *** 
<0.0001 *** 
Lund-
Kennedy 
score 
Whole population, mean ( sd) 
Superior turbinate biopsy 
No biopsy 
4.4 (2.7) 
4.2 (2.7) 
4.6 (2.7) 
2.1 (1.6) 
2.5 (1.8) 
1.5 (1.3) 
<0.0001 *** 
0.0002 *** 
<0.0001 *** 
VAS score 
on overall 
nose 
symptom 
Whole population, mean ( sd) 
Superior turbinate biopsy 
No biopsy 
6.5 (2.8) 
6.8 (2.6) 
6.2 (3.0) 
3.3 (2.7) 
3.4 (3.1) 
3.3 (2.2) 
<0.0001 *** 
0.0008 *** 
0.0005 *** 
VAS score 
on sense of 
smell 
Whole population, mean ( sd) 
Superior turbinate biopsy 
No biopsy 
5.9 (3.5) 
5.6 (3.4) 
6.3 (3.7) 
3.6 (3.3) 
3.6 (3.3) 
3.7 (3.4) 
<0.0001 *** 
0.0049 ** 
0.0066 ** 
NOSE 
score 
Overall, mean ( sd) 
Superior turbinate biopsy 
     No biopsy 
12.9 (5.9) 
13.8 (5.9) 
12.3 (5.9) 
5.6 (4.9) 
5.8 (5.5) 
5.3 (4.3) 
<0.0001 *** 
0.0004 *** 
0.0018 ** 
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Table 5 Effect of the sup’ turbinate biopsy on UPSIT value 
 
Analysis by 2-way ANOVA. 
Biopsy has no interaction with FESS (p=0.6376). 
Biopsy does not affect the UPSIT value (p=0.1468). 
FESS does not affect the UPSIT value (p=7032). 
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Table 6 Effect of the sup’ turbinate biopsy on UPSIT percentile 
 
Analysis by 2-way ANOVA. 
Biopsy has no interaction with FESS (p=0.7492). 
Biopsy does not affect the UPSIT percentile (p=0.9693). 
FESS does not affect the UPSIT percentile (p=0.5659). 
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Table 7 Effect of the sup’ turbinate biopsy on SNOT-22 
 
Analysis by 2-way ANOVA. 
Biopsy has no interaction with FESS (p=0.9368). 
Biopsy does not affect the SNOT-22 (p=0.0921). 
FESS affects the SNOT-22 significantly (p<0.0001) *** (improvement). 
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Table 8 Effect of the sup’ turbinate biopsy on Lund-Kennedy endoscopic score 
 
Analysis by 2-way ANOVA. 
Biopsy and FESS interact on the Lund-Kennedy score (p=0.0416). 
Biopsy does not affect the Lund-Kennedy endoscopic score (p=0.3724). 
FESS affects the Lund-Kennedy endoscopic score significantly (p<0.0001) *** 
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Table 9 Effect of the sup’ turbinate biopsy on overall Visual Analogue Scale 
 
Analysis by 2-way ANOVA. 
Biopsy has no interaction with FESS (p=0.5944). 
Biopsy does not affect the overall VAS (p=0.4534). 
FESS affects the overall VAS significantly (p<0.0001) *** (improvement). 
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Table 10 Effect of the sup’ turbinate biopsy on the NOSE score 
 
Analysis by 2-way ANOVA. 
Biopsy has no interaction with FESS (p=0.6091). 
Biopsy does not affect the NOSE score (p=0.3291). 
FESS affects the NOSE score significantly (p < 0.0001) *** (improvement). 
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Table 11 Effect of the sup’ turbinate biopsy on Visual Analogue Scale on sense of Smell 
 
Analysis by 2-way ANOVA. 
Biopsy has no interaction with FESS (p=0.6835). 
Biopsy does not affect the VAS on sense of Smell (p=0.5920). 
FESS affects the VAS on sense of Smell significantly (p<0.0001) *** (improvement). 
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Table 12 Is there a correlation between the Visual Analogue Score on sense of Smell and 
the UPSIT value? 
 
No correlation (Spearman R
2
 = 0.2332) 
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Table 13 Is there a correlation between the Visual Analogue Score on sense of Smell and 
the UPSIT percentile? 
 
No correlation (Spearman R
2
 = 0.2398) 
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Table 14 Effect of Polyps on UPSIT value 
 
Analysis by Mann-Whitney test. 
Patients with polyps have significantly lower UPSIT results pre-operatively (p<0.0001)***. 
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Table 15 Effect of polyps on UPSIT value, Analysis by 2-way ANOVA. 
Polyps have no interaction with FESS on UPSIT results (p=0.3848). 
Polyps affect significantly the UPSIT value (p<0.0001) ***. 
FESS does not affect the UPSIT value (p =0.4477). 
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Table 16 Effect of Polyps on UPSIT percentile 
 
Analysis by Mann-Whitney test. 
Patients with polyps have significantly lower UPSIT percentile pre-operatively 
(p<0.0001)***. 
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Table 17 Analysis by 2-way ANOVA. 
Polyps have no interaction with FESS on UPSIT percentile (p=0.8227). 
Polyps affect significantly the UPSIT percentile (p<0.0001) ***. 
FESS does not affect the UPSIT percentile (p =0.7036). 
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Table 18 Effect of Smoking on UPSIT value 
 
Analysis by Mann-Whitney test. 
No difference between smokers and non-smokers on the UPSIT results pre-operatively 
(p=0.4213). 
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Table 19 Analysis by 2-way ANOVA. 
Smoking has no interaction with FESS on UPSIT results (p=0.2834). 
Smoking could affect UPSIT value (p=0.0320). 
FESS does not affect UPSIT value (p =0.2938). 
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Table 20 Effect of Smoking on UPSIT percentile 
 
Analysis by Mann-Whitney test. 
No difference between smokers and non-smokers on the UPSIT percentile pre-operatively 
(p=0.9615). 
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Table 21 Analysis by 2-way ANOVA. 
Smoking has no interaction with FESS on UPSIT percentile (p=0.1395). 
Smoking does not affect UPSIT percentile (p=0.3299). 
FESS does not affect UPSIT percentile (p =0.1888). 
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Table 22 Effect of the age on UPSIT value 
 
No correlation between age and UPSIT value 
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Table 23 Effect of gender on UPSIT value 
 
Analysis by Mann-Whitney test. 
No difference between male and female on the UPSIT results pre-operatively (p=0.2222). 
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Table 24 Patient Data on subgroup analysis within the CRS cohort of patients 
 
 
 
Patients Data 
Demographic 
Data 
Total, No 113 
Age, mean ( sd), yr 46.3 ( 14.9) 
Sex, No (%) 48 ♀ (42.5%) 
65 ♂ (57.5%) 
Clinical Data Polyposis, No (%) 
Revision surgery, No (%) 
Smoking, No (%) 
60 (53.1%) 
13 (11.5%) 
24 (21.2%) 
CT-scan Lund-Mackay score, mean ( sd)  10.9 ( 6.9) 
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Table 25 Outcome measures on subgroup analysis within the CRS cohort of patients 
 
 
 
Outcome measures pre-operative post-operative p 
UPSIT 
(value) 
Whole population, mean ( sd) 
CRSsNP 
CRSwNP 
25.5 (9.9) 
29.5 (7.8) 
21.9 (10.4) 
26.6 (9.7) 
29.1 (8.1) 
24.3 (10.5) 
0.38 ns 
0.34 ns 
0.04 * 
NOSE score Whole population, mean ( sd) 
CRSsNP 
CRSwNP 
61.2 (30.6) 
54.2 (32.7) 
67.2 (27.7) 
27.8 (25.4) 
31.8 (27.2) 
22.7 (4.7) 
<0.01 *** 
0.01 * 
<0.01 *** 
SNOT-22 
score 
Whole population, mean ( sd) 
CRSsNP 
CRSwNP 
53.4 (24.8) 
52.8 (26.3) 
54.0 (23.7) 
28.9 (23.8) 
32.5 (25.4) 
25.8 (22.2) 
<0.01 *** 
<0.01*** 
<0.01*** 
Lund-
Kennedy 
score 
Whole population, mean ( sd) 
CRSsNP 
CRSwNP 
4.6 (2.7) 
3.2 (2.3) 
5.7 (2.6) 
2.1 (1.7) 
2.1 (1.4) 
2.1 (1.8) 
<0.01 *** 
0.15 ns 
<0.01 *** 
VAS score 
on overall 
nose 
symptom 
Whole population, mean ( sd) 
CRSsNP 
CRSwNP 
6.6 (2.8) 
6.3 (2.7) 
6.9 (2.8) 
3.4 (2.8) 
4.4 (2.8) 
2.4 (2.5) 
<0.01 *** 
0.04 * 
<0.01 *** 
VAS score 
on sense of 
smell 
Whole population, mean ( sd) 
CRSsNP 
CRSwNP 
6.0 (3.5) 
4.4 (3.5) 
7.4 (2.8) 
3.7 (3.4) 
2.5 (3.0) 
5.0 (3.4) 
<0.01 *** 
0.05 ns 
<0.01*** 
 
 
 
 
 
 
 
 
 
 93 
 
 
 
 
 
 
 
 
Table 26 Comparison of SNOT22 and UPSIT on subgroup analysis within the CRS 
cohort of patients 
 
 
 
Table Interpretation 
Our population cohort, summarized in Table 2, was representative of the population 
undergoing sinus surgery in a tertiary referral hospital. Out of the 136 patients for whom 
inclusion in our study was offered, 131 completed the UPSIT test and were randomized for 
superior turbinate biopsy, 2 could not complete the UPSIT test due to language barrier, 1 did 
not have time to complete the UPSIT test, 1 patient declined to participate and 1 planned 
intervention was cancelled. Out of the 131 subjects included in our study, 65 underwent a 
superior turbinate biopsy and 66 were randomized for the control group. Demographic data, 
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severity of disease, co morbidities and surgical indications were comparable in the two 
groups. 
 
There was no difference demonstrated between the groups for baseline UPSIT scores. Biopsy 
of the superior turbinate did not affect the UPSIT result (p=0.1468) and had no interaction 
with sinus surgery (p=0.6376). Sinus surgery failed to improve the UPSIT results in all 
patients (p=7032), with no difference between biopsy and control groups. Adjustment for age 
and sex using UPSIT percentile did not affect these findings. However, the evaluation of the 
sense of smell on a visual analogue scale subjectively improved in both groups after sinus 
surgery. 
 
There was no significant difference between groups in terms of secondary endpoint measures 
(Lund-Kennedy endoscopic outcome, SNOT-22, VAS, NOSE score). There were no 
differences between the groups with respect to quality of life, patient’s reported olfactory 
measure or endoscopic evaluation. However, there was no correlation between the subjective 
sense of smell reported on a visual analogue scale and the objective evaluation by UPSIT. 
Superior turbinate biopsy did not affect the subjective sense of smell (p=0.5920) and had no 
interaction with sinus surgery (p=0.6835). Sinus surgery was able to improve significantly the 
subjective sense of Smell (p<0.0001) in both groups, independently of superior turbinate 
biopsy. Patients with nasal polyps had significantly lower baseline olfactory scores compared 
to patients without nasal polyps, but no effect of biopsy was detected between the groups on 
any of the outcome measures. 
 
On sub group analysis of the CRS cohort, the population was consistent with the patients 
undergoing sinus surgery in a tertiary referral hospital (Table 24). Out of the 128 patients for 
whom inclusion in our study was offered, 113 agreed to enter the study. Half of the patients 
had chronic rhinosinusitis with nasal polyps. Mean Lund-Mackay score was 10.9 (severe 
chronic sinusitis on CT scan). The Lund-Mackay score was higher in the CRSwNP patient 
group (mean 14.9 ± 5.8) compared to the CRSsNP group (mean 6.4 ± 5.3). Mean Lund-
Mackay score severity was not correlated to the UPSIT baseline score. However, patients 
with nasal polyps had lower baseline UPSIT scores compared to patients without polyps 
(p<0.0001). Through analyzing correlations between UPSIT and scores derived from the 
Lund Mackay (LM) and Lund-Kennedy (LK) grading systems a negative correlation was 
found for all scores preoperatively (Spearman r=-0.55 for LM scores and r=-0.50 for LK 
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scores). The UPSIT score was not significantly different in smoking or non-smoking patients 
in our population. Equally, in our population, age was not correlated to the baseline UPSIT 
score. The influence of chronic rhinosinusitis on olfaction measured by UPSIT was likely to 
be stronger than the effect of age and tobacco in our population. 
 
The outcomes as summarized in table 25 demonstrate that the UPSIT score in the CRSwNP 
subgroup improved significantly after endoscopic sinus surgery (Wilcoxon p = 0.0428). A 
similar significant improvement in the VAS ‘sense of smell’ measurement was demonstrated 
in the CRSwNP subgroup (Wilcoxon p = 0.0004). However, although the UPSIT and VAS 
‘sense of smell’ outcomes improved in the CRSsNP subgroup they were not significant.   
A significant improvement in the subjective olfaction scored by the visual analogue scale was 
also seen in the general CRS population (Wilcoxon p <0.0001).  However, in the whole CRS 
population, olfactory improvement as measured by UPSIT was not significant after surgery.  
The UPSIT score did not change following surgery in 12.7% of the CRS cohort, it improved 
in 46.0% and worsened in 41.3%. However, the outcomes differed on perceived evaluation of 
olfaction as rated on the VAS ‘sense of smell’ measurement whereby it  improved in 72.5% 
of the cohort, did not change in 13.7% patients and worsened in 13.7% patients following 
surgery. The SNOT-22 score, the surgeon reported endoscopic evaluation, the NOSE score 
and the visual analogue scale improved significantly after surgery in the whole population. 
The quality of life measured by SNOT-22 improved in 84.5% patients and decreased in 
15.5% patients after surgery.  
 
When reviewing the subgroups, baseline scores were seen to be worse in the polyp subgroup, 
but surgical improvement was especially marked in this subgroup. Among polyp patients, 
54.5% improved their UPSIT score, while 12.1% did not change and 33.3% worsened after 
surgery. Subjective olfaction was even better with 81.4% of polyp patients reporting an 
improvement on visual analogue scale, 14.8% patients without change and 3.7% patients with 
worsening of olfaction. Improvement of quality of life was observed in 90.9% of polyp 
patients. The SNOT-22 decreased in 9.1% of the polyp patients. 
 
SNOT-22 change and UPSIT change after surgery were correlated. More than 30% of the 
SNOT-22 variance was related to UPSIT improvement after surgery in polyps patients (r2 = 
0.379, p<0.001, Table 26). A correlation between the ‘sense of smell’ Visual Analogue Score 
and the UPSIT value was not demonstrated (Spearman R2 = 0.13) A correlation between the 
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NOSE scale and UPSIT score (r2 = 0.01, p = 0.402) equally was not demonstrated. There 
was no relationship between NOSE change after surgery and UPSIT change after surgery (r2 
= 0.223, p = 0.0032). A correlation between SNOT-22 change (Y-axis) and UPSIT change 
after surgery (Y-axis) in the CRSwNP was demonstrated in Table 26. SNOT-22 change and 
UPSIT change after surgery were fairly correlated, and more than 30% of the SNOT-22 
variance was related to UPSIT improvement after surgery. 
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Table 27 Morbidity rates following surgery; primary and secondary haemorrhage and 
CSF leakage. 
 
Date FESS FESS Bx Primary 
Haemorrhage 
Secondary 
Haemorrhage 
CSF 
leak 
 
Sept/Oct 
2012 
5 5 0 0 1 (Bx)  
Nov/Dec 
2012 
6 5 0 0 0  
Jan /Feb 
2013 
9 8 0 1 Bx 
 
0  
Mar/Apri 
2013 
5 6 0 0 0  
May/June 
2013 
5 5 0 0 0  
July/Aug 
2013 
8 8 0 0 0  
Sept/Oct 
2013 
5 5 0 1 (non biopsy) 0  
Nov/Dec 
2013 
6 5 0 0 0  
Jan/Feb 
2014 
7 8 0 0 0  
Mar/Apr 
2014 
5 5 0 0 0  
 
According to Table 27 the primary haemorrhage rate was zero percent in both groups and the 
incidence of secondary haemorrhage rates was less than 1% in each group. The incidence of 
CSF leak was less than 1% in the biopsy group if the single superior segment biopsy is also 
included in this analysis but is zero percent if only the middle section harvesting technique is 
included. A significant difference in complication rates between the two groups was not 
demonstrated on Mann-Whitney evaluation p<0.05%. 
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CHAPTER 4 
 
DISCUSSION 
 
The primary hypothesis which stated that olfactory harvesting is ‘patient safe’ and does not 
incur a detriment to the patient’s nasal function and specifically does not reduce the patient’s 
sense of smell has been accepted as demonstrated by the results of this thesis. In addition we 
have demonstrated that patient morbidity and beneficial outcomes following harvesting 
human olfactory nasal mucosa during ESS is statistically the same compared to the outcomes 
of standard ESS without biopsy in this prospective controlled level 2b evidence based study. .  
 
The secondary hypothesis which stated that the effect of sinus surgery improves olfaction in 
both the CRSwNP and CRSsNP subgroups has also been accepted as demonstrated by the 
results of this thesis. In the CRSwNP subgroup , the patient’s perceived and measured sense 
of smell improved significantly following ESS and represents the most surgically responsive 
CRS subgroup as well as the most likely subgroup to improve the patient’s quality of life 
following an improved post operative olfactory response. This statistically significant 
olfactory improvement following surgery was not demonstrated in the CRSsNP subgroup. In 
addition we have uniquely demonstrated that the ‘NOSE’ patient reported outcome measure 
is a novel and sensitive outcome measure in the CRS population, however, it does not 
correlate with improved olfaction.  
 
Patient safety and nasal function, including olfactory outcomes, were not affected by 
unilateral resection of the middle section of the superior turbinate when compared to the 
outcomes of standard endoscopic sinus surgery without an olfactory biopsy. Importantly we 
have uniquely demonstrated that the patient’s quality of life and nasal patency remain 
unaffected following olfactory mucosa harvesting. This level 2b evidence analysis has not 
been performed before and will aid in the process of informed consent as well as promote 
future harvesting developments 
(122)
. 
 
One of our main concerns following the resection of the middle section of the superior 
turbinate was a potential reduction in the patient’s sense of smell owing to the inevitable loss 
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of olfactory mucosa. A perceived or measured olfactory loss was not demonstrated in this 
study and hence we can assume the olfactory loss was not significant enough for the patient 
to notice, which is in keeping with previous smaller studies 
(5;123)
. Interestingly the perceived 
olfactory ability from healthy individuals and rhinological patients is generally poor. A recent 
study demonstrated even amongst healthy well functioning cognitive middle aged adults that 
79% of this sample, with objectively assessed olfactory dysfunction, reported normal 
olfactory function 
(124)
, a similar but less dramatic finding was also found in patients with 
rhinological pathology whereby 33% of patients felt had a normal sense of smell actually 
were hyposmic 
(76)
. 
 
 
The need to harvest olfactory tissue without causing harm to the patient was fundamentally 
evaluated in this thesis. The ongoing dilemma, on one hand, is the need to optimize yield 
rates of olfactory tissue, in particular OEC yield rates and yet on the other hand it’s to ensure 
patient safety and not disadvantage the donor with reduced nasal function ability. We have 
already demonstrated in previous work that OEC yield rates are higher when biopsies are 
harvested closer to the skull base as well as in younger patients with less sinonasal disease  
however subsequent patient safety has not been robustly evaluated 
(4)
.  In this thesis it was 
vital to have this real time information on OEC yield rates whilst at the same time optimising 
our harvesting technique.  
 
Although the harvesting of the middle section of the superior turbinate is shown to be safe 
there were initial problems during its development. In the early stages of the harvesting 
technique the superior aspect of the superior turbinate was trialed and this encroached 
directly onto the skull base with an immediate CSF leakage. This was the only CSF leak 
encountered during the study and the superior aspect of the superior turbinate was 
immediately abandoned. The defect was reconstructed with fascia lata and a free mucosal 
flap taken from the inferior turbinate. The patient was discharged home without further 
complications and made a full and beneficial recovery. As shown in figure 32 the superior 
section of the superior turbinate is in close proximity with the skull base and olfactory bulb 
and therefore will inevitably result in a CSF leak if harvested. It has been acknowledged that 
the evolution of this technique, for good science engineering reasons, may have confounded 
the results to a minor degree, however the majority of the biopsies did involve the middle 
section of the superior turbinate. 
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Figure 32 Coronal MRI scan highlighting close proximity of superior turbinate to skull base 
 
 
 
 
 
In this study the patient’s perceived and measured sense of smell were statistically unaffected 
following their olfactory biopsy. Interestingly, the patient’s subjective sense of smell 
improved significantly in both surgical groups whereas their measured or psychophysical 
sense of smell equally also improved but not significantly. A correlation between the 
patient’s UPSIT outcomes and their respective smell VAS scores was not found. It would 
therefore appear that the size of our olfactory biopsy and subsequent loss of olfactory tissue 
did not impact significantly on the remaining olfactory function. The average surface area of 
our olfactory biopsy measured 2 by 2 mm in size (4mm squared) and included the whole of 
the middle section of the superior turbinate. As previously described the average surface area 
of the human olfactory mucosa surface area is approximately10 to 20mm squared in each 
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cavity. According to Kachramanoglou
 
the average yield rate of OECs was 7.5% with an 
overall OEC cellular proportion of 25% 
(4)
. Assuming on average 25% of the harvested area 
contained olfactory mucosa then this would equate to a potential histological loss of 1mm 
squared from a potential olfactory maximum of 40mm squared. This equates to less than 5% 
of the total olfactory mucosa being harvested.  
 
The alternative theory would argue that the biopsied olfactory area had regenerated and 
repopulated the olfactory epithelium however this argument is doubtful owing to the lack of 
regeneration of the biopsied middle section of the superior turbinate as seen in figure 33. In 
this figure you can see the deficient middle section with a small adhesion as seen 
endoscopically 2 years post operatively. The mucosa has regenerated over the defect but the 
surface area has remained reduced owing to the lack of turbinate architecture. The question 
remains as to what is the maximum amount of olfactory tissue which could be harvested 
without incurring a functional loss. 
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Figure 33 Endoscopic photograph of a healed superior turbinate biopsy 2 years post 
harvesting 
Right 
superior
Turbinate
Post biobsy
 
 
 
 
On subgroup analysis within our CRS patient cohort, the UPSIT psychophysical 
measurement significantly improved following endoscopic sinus surgery (ESS) in the 
CRSwNP subgroup as well as the patient’s perceived VAS sense of smell. However, in the 
CRSsNP subgroup, the improved VAS and UPSIT measurements were not significant. 
Hence, the CRSwNP subgroup represents the most surgically responsive group to improved 
olfaction.  
Whilst the total CRS population, including both CRSwNP and CRSsNP subgroups, olfactory 
improvement as measured by the UPSIT was not significant after surgery whereas the VAS 
sense of smell score did improve significantly. However, the UPSIT and VAS ‘sense of 
smell’ evaluations did not correlate. Interestingly, the SNOT 22 outcome   significantly 
improved in both subgroups following surgery and importantly a positive relationship 
between improved SNOT 22 outcomes and improved UPSIT measurements in the CRSwNP 
sub group was demonstrated 
(125)
. On further sub-group analysis, the impact of smoking, age 
and gender were not shown to affect baseline olfaction nor olfactory function following 
 103 
 
surgery, suggesting that sinus disease was the most important contributor to impaired 
olfaction in our cohort, overshadowing other factors.  
We indirectly assessed the effect of polyp size on olfaction by analyzing the correlation of 
UPSIT with the Lund-Mackay CT and Lund-Kennedy endoscopic scores. A negative 
correlation was demonstrated for all scores preoperatively (Spearman r=-0.55 for LM scores 
and r=-0.50 for LK scores) and thereby implying a higher or more severe pre-operative polyp 
score is moderately correlated with a lower olfactory performance 
(125)
. 
The majority of our patients were hyposmic prior to surgery in keeping with our pre-
operative UPSIT scores which averaged at 25.5 and according to the UPSIT  grading system 
a score of 25.5 reflected a moderate to severe hyposmia 
(121)
.However given the tertiary 
referral nature of our practice, a more severe score may have been expected. Equally although 
the patient’s sense of smell improved following surgery the majority of the patients still 
remained hyposmic which is in keeping with current evidence. 
The findings in our CRS subgroup analysis are in agreement with results from a recent study 
evaluating olfactory outcomes in CRSwNP and CRSsNP subgroups. A significant olfactory 
improvement in the CRSwNP subgroup but not in CRSsNP subgroup was demonstrated 
using the Sniffin Stick identification test 
(96)
. Rowe-Jones et al performed a 5 year prospective 
study, of whom 75% were CRSwNP, which demonstrated a significant improvement in 
measured olfaction at 2 years post surgery and then became non significant at 5 years 
(99)
. 
Interestingly Rudolf Briner et al. also demonstrated a significant improvement in olfaction 
following ESS which remained significant long term
(94)
. Lund et al also demonstrated  a 
significant improvement in olfactory function following ESS 
(98)
.
 
 
Shriever et al in 2013 looked at the effects of nasal surgery, including both sinus surgery and 
septal surgery, on olfaction using the 16 item odor identification ‘Sniffin’ stick test. At 3.5 
months post operatively there was a significant improvement in the sinus surgery arm as 
opposed to a non-significant improvement in the septal surgery arm and interestingly they 
both became non-significant at 12 months. They also found that polyps and eosinophilia were 
good prognostic factors for olfactory outcome improvement and equally in the non-polyp 
group, the improvement was not significant
(103;126)
. Randhawa et al uniquely demonstrated a 
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significant improvement in olfactory function following functional septorhinoplasty surgery 
using sniffin sticks at 6 months.
(127) 
However, Rudmik and Smith performed a literature 
review on the efficacy of FESS in CRS-related olfactory dysfunction and concluded the 
evidence supporting its efficacy is equivocal and not significant 
(102)
. Interestingly there is 
also increasing evidence supporting early surgical intervention in medically refractory CRS 
whereby higher post operative healthcare needs are exhibited when the delay for surgery is 
longer 
(128)
. 
In our CRS subgroup study, measured UPSIT olfactory function did not change after surgery 
in 12.7% patients, improved after surgery in 46.0% patients and worsened in 41.3% patients. 
Interestingly on subjective olfaction measurements, improvement was seen in 72.5% patients, 
did not change in 13.7% patients and worsened in 13.7% patients after sinus surgery. Pade et 
al demonstrated an improvement in the sense of smell, as measured by Sniffin sticks in 23% 
of their post operative patients, no change was seen in 68%, and a decreased function was 
seen in 9% of the patients.
(129)
 Dealank et al. also demonstrated post-endoscopic sinus surgery 
olfactory improvements in 70% of their CRS population and olfaction changed for the worse 
in 8%.
(130)
 
 
 
The evaluation of our patient’s sense of smell was subjectively measured using both the 
UPSIT and VAS scoring methods and as a result were both open to potential patient bias and 
is a potential limitation of this study.  The UPSIT test was chosen in this study owing to its 
universal track record. It’s the most validated chemosensory testing or psychophysical 
technique used internationally and additionally evaluates the probability of malingering in 
our patient group. As a forced response test from 4 potential answers, there is a 1 in 4 chance 
of getting a correct answer and hence a score below 8 increases the probability of 
malingering. The UPSIT is therefore our screening test of choice and works on a scratch and 
sniff principle revolving around 40 different odours. It tests cognition at the same time 
(121)
.  
 
 
There were arguments originally pertaining to the UK validation of the original UPSIT which 
used names and smells which were culturally unfamiliar to the UK as well as other countries.  
As a result the unfamiliar smells and names of the US normative data could not be fully 
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transferable. This has been improved with the provision of the British version 
(131)
. In this 3
rd
 
version the American scents which were culturally unfamiliar were replaced with commonly 
known UK smells. The UPSIT database has also been further improved with the inclusion of 
an expanded normative database of 4000 men and women. This enables to provide normative 
data down to the 5
th
 percentile for each 5 year age category with a classification of hyposmic 
patients into mild, moderate and severe with male; mild 30-33, moderate 26-29, severe 19-25, 
and females; mild 31-34, mod 26-30, severe 19-25. This additional percentile information has 
enabled titration of the patient’s sense of smell outcomes according to their age and gender 
and following this their sense of smell remains unchanged following olfactory biopsy. We did 
not have a single case of anosmia in our 131 surgical cohort group and therefore exhibited a 
zero percent anosmic risk. Interestingly though the majority of our patients were hyposmic 
prior to surgery and although their sense of smell improved they still remained hyposmic 
following surgery. We also explored the usage of other chemosensory or psychophysical 
testing techniques such as the Sniffin stick test which we decided not to go with because at 
the time it was not widely used and its validation was not as universal when compared to the 
UPSIT. Sniffin sticks have been validated in the UK and can be additionally used to 
determine olfactory thresholds and discrimination 
(132)
. There is also an argument for testing 
olfaction unilaterally as opposed to bilaterally however it was decided if a difference were to 
be seen it would be picked up in either case as well as the added burden and additional 
compliance in technique we felt there was not a need  to do this 
(133)
.  
 
There is now a growing acceptance that patient’s views are essential in the delivery of high 
quality care. In our study, patient reported outcomes measured both symptom specific 
complaints using VAS scoring techniques and disease specific health related outcomes using 
the SNOT 22 questionnaire. Each method required the patient to measure their symptom 
severity and its impact on their quality of life at that specific moment in time. The same 
questionnaires were repeated at 6 months enabling a quantitative comparison pre and post 
surgery. Studies have shown that symptom severity scored at 3 months are very similar to 
those scored at 12 months and as a result we used 6 months as the ideal time to follow 
patients up and repeat measurements 
(134)
. This also allowed for optimum patient capture. 
 
A well-established approach to understanding symptom severity is with the use of a Visual 
Analogue Scale (VAS) which is an EPOS recommendation for determining severity of 
disease 
(74)
. It allows patients to subjectively rate their symptoms on a 10cm linear scale, 
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where 0 corresponds to no symptoms and 10 is the most severe.  A score of 5 is generally 
considered significant. However, the severity of symptoms may or may not correlate with the 
impact of the nasal symptoms on an individual’s quality of life, and therefore a variety of 
additional quality of life (QOL) measures were incorporated. Of these, the Sino-nasal 
Outcome Test (SNOT-22) is one of the most widely used. It is a validated 22 item health 
status questionnaire which was originally designed for assessment relating to sinonasal 
disease 
(120)
. The SNOT-20 was developed from the 31-item Rhinosinusitis Outcome Measure 
(RSOM-31) by removing 11 items thought to be less important and forming the SNOT-20. 
The addition of a further two items of interest (nasal obstruction and olfaction) formed the 
SNOT-22, which has been demonstrated to be reliable, valid, and responsive 
(120)
. It has since 
been validated for monitoring response to treatment for patients with chronic rhinosinusitis, 
septal surgery and septorhinoplasty 
(108)
. 
 
The SNOT 22 was shown to have a median value of 7 in healthy volunteers and a mean of 42 
in CRS patients from a cohort of 3128 patients undergoing FESS
(120)
. In a separate study but 
using a similar control group the mean SNOT 22 value was 9 
(135)
. The mean post operative 
score of 28 at 5 years was similar to that at 3  and 12 months post operatively and represents 
an overall 14 point improvement
(134)
. This SNOT 22 result is similar to ours although our pre 
operative value of 51.9 was higher and the post operative value of 29.1 was very similar and 
creating a larger point improvement of 22. Three of our patients did not improve following 
surgery with regards to their Snot 22. Interestingly, Poetker et al, demonstrated that their 
patients with nasal polyps scored lower on their snot 22 scores when compared with CRS 
without polyps even though they scored higher on their Lund Mackay scores 
(136)
. 
 
The NOSE questionnaire provides a further validated nasal blockage symptom specific 
questionnaire which specifically assesses the symptom of nasal obstruction and its 
consequences. This brief questionnaire consists of five questions which are used to rate the 
burden of nasal obstruction during the past month, with each question being scored from 0 
(not a problem) to 4 (severe problem). The first question asks whether you suffer with nasal 
congestion or stuffiness, the second questions asks about nasal blockage or obstruction, the 
third question asks about trouble breathing through your nose, the fourth question asks about 
trouble sleeping and the fifth asks about whether you are unable to get enough air through the 
nose during exercise or exertion.  It has been  validated as a quality of life measurement in 
nasal septal surgery, functional septorhinoplasty and nasal valve surgery and therefore 
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provides another potential useful measurement in determining whether there has been a 
meaningful subjective change following intervention 
(104)
.   
 
 
Most et al categorised the nose score according to severity and divided the results into mild 
(5-25), moderate (30-50) and severe (55-75) or extreme (80-100) 
(137)
. It was concluded that 
patients scoring less than 30 or 6 if not multiplied by 5 was the best indicator for not suffering 
with nasal blockage. Rhee et al looked at normative data using the NOSE score as well as the 
VAS score 
(138)
. The mean asymptomatic individual NOSE and VAS scores were 15 
(17)
 and 
2.1 (1.6). The mean (SD) NOSE and VAS scores for a patient with nasal obstruction were 65 
(22) and 6.9 (2.3), respectively. The mean postsurgical NOSE and VAS scores were 23 (20) 
and 2.1 (2.2), respectively. Interestingly these results are very similar to our pre and post 
NOSE scores which measured 12.9 and 5.6 (before multiplying by 5). 
This study was the first to evaluate the NOSE scale as an outcome measure for nasal 
blockage in the CRS population. The NOSE scale significantly improved in both the CRSsNP 
and CRSwNP subgroups following endoscopic sinus surgery, although a direct relationship 
with improved olfaction was not demonstrated. The NOSE questionnaire provides another 
validated symptom-specific quality of life questionnaire, which specifically assesses the 
symptom of nasal obstruction and its consequences 
(125)
.  
In this study the endoscopic appearances of the nasal cavity improved significantly at 6 
months post operatively in both surgical arms and a difference between the two groups was 
not seen. A statistically significant improvement in the Lund and Kennedy score was 
demonstrated with a significant improvement in oedema, polyposis and discharge following 
endoscopic sinus surgery with and without biopsy. As a result our olfactory harvesting 
technique did not exhibit a significant effect on the sinus cavity appearances post operatively.  
 
Although the surgeon reported Lund and Kennedy scores reflect a significant improvement in 
the biopsy and non-biopsy arms, it needs to be acknowledged that the method of nasal 
decongestion used in the operating theatre was not always the same as that used in clinic 
during the post operative evaluation and may have introduced a confounding factor 
particularly in the CRSsNP subgroup analysis. However, given the large sample size and the 
fact decongestant was always used both pre and post operatively it is unlikely to be 
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significant.  
 
 
The key however is one of prediction and looking for the predictive factors indicating 
likelihood of improvement 
(101)
. Litvack et al in their cohort of patients found age and nasal 
polyposis key predictive factors; 64 % of men and women between the ages of 18 and 64 had 
olfactory dysfunction whereas 95% of patients older than 65 years had olfactory dysfunction. 
There was no significance found with gender. The risk of hyposmia increases with additional 
asthma and smoking comorbidity. Allergic rhinitis and structural defects did not affect sense 
of smell. The incidence of smoking among our population group was very similar to the 
normative UPSIT data and can therefore be reasonably extrapolated showing from our results 
that it does not have a significant effect on outcome. In our study we did not find that 
smoking affected olfactory function following surgery in either group and similarly we did 
not find a correlation with gender or age 
(122)
. 
 
 
Our findings do appear to agree with common opinion that hyposmia in CRS is not just a 
conductive problem but also a potential irreversible sensory disorder whereby even after 
clearing the conductive component the hyposmia remains. The sensory disorder is dependent 
on olfactory epithelium atrophy which is also dependent on age, disease severity and 
prolongation of disease and asthma. The current belief is to operate on these patients as soon 
as possible before the onset of irreversible disease progression 
(128;139)
.  
 
Importantly we have demonstrated that the patient’s sense of smell is statistically unaffected 
by olfactory mucosa harvesting surgery in the largest study performed so far. Our results are 
in keeping with other studies, albeit studies which have recruited smaller patient numbers and 
are also non-controlled. Say et el biopsied 31 patients and utilized the inferior segment of the 
superior turbinate and found that 12% of their patients had a decreased sense of smell post 
operatively which they concluded was not due to the harvesting procedure per se as the 
samples received from these patients did not contain olfactory tissue in the first place. There 
overall conclusion was that the sense of smell is unaffected by olfactory harvesting
(140)
. 
Equally in another study of 42 patients whereby the superior turbinate was punch-biopsied 
they also concluded the sense of smell was unaffected 
(123)
. 
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As well as demonstrating that our olfactory harvesting technique is safe and does not affect 
the patient’s sense of smell we have equally highlighted that the CRSwNP subgroup 
represents the most surgically responsive subgroup for olfactory improvement and this will 
improve the informed consent process for patients. Also by improving a patient’s sense of 
smell following surgery we can also expect a significant improvement in the patient’s quality 
of life in the CRSwNP subgroup. According to our data, up to one third of the SNOT-22 
variance was related to UPSIT change and not 1/22th as would be expected if it were just 
referring to the sense of smell. This would imply that impaired olfaction has a greater impact 
on quality of life than expected. 
 
However, olfactory impairment in CRS is not just a conductive problem which would explain 
the lack of correlation between improved olfaction and the improved NOSE scale outcome. 
Conversely, we have demonstrated a significant proportion of patients whose measured and 
perceived sense of smell became worse after surgery, which also needs to be explained at the 
time of informed consent. Equally the more severe the CRS presents pre-operatively then the 
likelihood of olfactory dysfunction also increases. Reassuringly we did not have a single case 
of post operative anosmia. 
One of the limitations of this study was the lack of pre-operative stratification of severity and 
duration of hyposmia, thus preventing a sub-group analysis of olfactory improvement taking 
into account these variables. In addition the UPSIT evaluation may not have been sensitive 
enough for olfactory loss detection as it only measures olfactory identification as opposed to 
the additional outcomes of olfactory threshold and discrimination unlike the Sniffin stick 
evaluation which measures all three. The mismatch between our measured UPSIT outcomes 
and what the patient perceived as measured by the VAS olfactory outcomes may relate to the 
sensitivity of the UPSIT evaluation. With the use of  Sniffin sticks, Pade and Hummel, 
deemed an olfactory improvement of three or more points as a significant change and hence a 
similar strategy should be recommended  for future UPSIT measurements 
(129)
. 
 Another limitation of this study was the lack of a true objective olfactory outcome 
measurement such as event-related olfactory potentials or functional MRI scanning owing to 
the fact we did not have access to this technology. Equally we did not correlate the NOSE 
scale outcome to an objective measure of nasal airflow such as a Nasal Inspiratory Peak Flow 
(NIPF) which will be incorporated in future studies.  
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A lack of patient randomization was a limitation of this study design. At the start of this study 
patients were initially randomised but those allocated to olfactory harvesting were declining 
more than originally anticipated. Consequently a more pragmatic approach was adopted 
whereby all patients were invited to undergo olfactory biopsies and those who declined were 
placed in the control group. The reason for the initial adoption of randomisation was so as to 
achieve a higher evidence based impact to the study.  
 
One of the statistical limitations of this study lay in the presumption that the power 
calculation for the primary hypothesis was automatically the same as that for the secondary 
hypothesis whereby in effect they should have been calculated separately. Reassuringly the 
sample size was large in both groups, as was the effect size, and therefore should not have 
had a significant impact. Similarly, although the data for outcomes in rhinology are typically 
non-parametric in presentation and the majority of the statistical methods employed in this 
thesis were of non-parametric design, it needs to be acknowledged that the parametric 2 way 
ANOVA was still employed. The 2 way ANOVA was used owing to the fact we were 
specifically dealing with the same patient population group with similar variance and the 
sample size was large. In this case the 2 way ANOVA works well with continuous data 
which is non-parametric, however, it is acknowledged that a non-parametric test should have 
also been considered. Equally to prevent confusion over patient recruitment for the CRS 
analysis as shown in table 2, the demographic number of CRS patients amounted to 97 and 
yet 113 were recruited into the CRS study. This discrepancy has arisen through the additional 
patients who were also recruited from the ‘other patients’ within table 2, for example, those 
who had fungal infection or other disease processes which may have equally presented with 
CRS.   
 
Our olfactory harvesting process has undergone continual refinement so as to maximize yield 
rates and maintain safety and function, and as previously discussed in the interest of good 
engineering science, this may have confounded the results albeit most likely non-significantly 
as the technique was refined. In this study we had solely analysed the middle section of the 
superior turbinate which is predominantly supplied by the lateral olfactory bundles as they 
exit the nasal cavity. In order to obtain a larger sample it could be argued that the lower half 
of the superior turbinate could have been harvested and this would involve only one 
horizontal incision and a surgically much easier vertical posterior incision. The advantages of 
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this further refinement would be an easier surgical excision and more olfactory tissue 
harvested.  
 
An area of expansion which is currently being refined involves harvesting the medial 
olfactory bundles which course up the septal perpendicular plate and enter the cribiform 
foramen as shown in figure 34. This septal mucosa area should contain a higher proportion of 
olfactory neurons and olfactory ensheathing cells owing to their convergence as they exit the 
nasal cavity via the cribiform fossa. This region which lies directly beneath the cribiform 
fossa can only be surgically accessed when exposing the anterior skull base and frontal sinus 
ostia with the assistance of image guidance techniques and is commonly visualized when 
performing the modified Lothrop technique. In this technique the frontal sinus floor and inter-
sinus septum are drilled out and fashioned into a single opening enabling excellent exposure 
of the anterior skull base and olfactory prominence. The above refinement still preserves the 
extradural harvesting approach although current clinical studies have utilized the intradural 
olfactory bulb harvesting technique with very promising clinical efficacy. In this clinical 
study a patient’s olfactory bulb OECs were transplanted into their severed spinal cord with 
additional peripheral nerve grafting working on the premise a higher OEC yield is obtained 
from the olfactory bulb 
(141)
. 
Figure 34 
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Currently, olfaction has been shown to reflect the general neurological well-being of a person 
and its dysfunction could act as an early warning sign for a neurodegenerative dysfunction 
such as in Alzheimers disease. Hence, this biopsy technique could be utilized in the diagnosis 
and potential treatment of neurodegenerative diseases 
(142)
. In addition the cause for anosmia 
in our rhinological practice and the reason as to why it can remain irreversible is an ongoing 
medical challenge; bearing in mind it also exhibits a paradoxical and exceptional regenerative 
ability. There is also an ongoing quest to look at new ways to treat anosmia and consequently 
there will be a need to perform histological analysis of olfactory epithelium in such patients 
so as to determine causation and help inform treatment.  
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CONCLUSIONS 
 
The primary hypothesis was shown to be true and the results from this thesis demonstrate  
that olfactory harvesting is ‘patient safe’ and does not incur a detriment to the patient’s nasal 
function and specifically does not reduce the patient’s sense of smell. In this prospective 
controlled  level 2b evidence based  study we have demonstrated that patient morbidity and 
beneficial outcomes following harvesting human olfactory nasal mucosa during ESS is 
statistically the same compared to the outcomes of standard ESS without biopsy. 
 
The secondary hypothesis which stated that the effect of sinus surgery improves olfaction in 
both the CRSwNP and CRSsNP subgroups has also been accepted as demonstrated by the 
results of this thesis. In the CRSwNP subgroup , the patient’s perceived and measured sense 
of smell improved significantly following ESS and represents the most surgically responsive 
CRS subgroup as well as the most likely subgroup to improve the patient’s quality of life 
following an improved post operative olfactory response. This statistically significant 
olfactory improvement following surgery was not demonstrated in the CRSsNP subgroup, 
although olfaction still improved. In addition we have uniquely demonstrated that the 
‘NOSE’ patient reported outcome measure is a novel and sensitive outcome measure in the 
CRS population, however, it does not correlate with improved olfaction.  
 
The future aims are to look at new ways to treat anosmia and help diagnose 
neurodegenerative diseases and the need to perform safely histological analysis of olfactory 
epithelium in such patients will help improve and inform new treatments. 
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A 
Consent form 
 
Patient information sheet 
    
 
 
CONFIDENTIAL 
 
Patient Information Sheet 
Version 6 
26
th
 April 2015 
 
THE SOURCE, CULTURE AND CHARACTERISATION OF HUMAN 
OLFACTORY ENSHEATHING CELLS OBTAINED FROM BIOPSIES OF NASAL 
MUCOSA. 
 
We would like to invite you to take part in a research project. Before you decide, it is 
important for you to understand why the research is being done and what it will involve. 
Please take time to read the following information carefully and discuss it with others if you 
wish. Ask us if there is anything that is not clear or if you would like further information. 
Take time to decide whether or not you wish to take part.  
 
 
Background to the study 
 
“Olfactory ensheathing cells” are a unique group of cells that are found in the brain and nose, 
which can repair damaged nerve fibres. If these cells are transplanted into patients with 
damaged nerves or spinal cords, it may be possible to cure injuries which were previously 
untreatable. If we can learn how to obtain these cells from the nose and purify them in the 
lab, then in the future it might be possible to take cells from the nose of a patient with spinal 
cord injury and place them into the spine to help repair the damage and make them walk 
again.  
 
However it is first necessary to find a safe and reliable way to obtain these cells from 
patients, and check if they can repair nerves in a similar way to previous laboratory and 
animal studies. We are studying a method for obtaining and growing these cells, taken from 
the inside of the nose, close to the area of your operation. 
This work is sponsored by DePuy Spine Ltd and two charitable organisations (Spinal 
Research and the British Neurological Research Trust). 
 
 
What will be involved? 
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If you agree to be in the study, your pituitary or nose operation will not be affected. The only 
difference is that two small biopsies (samples of tissue, about 3mm cubes) will be taken from 
the inside of the nose during the surgery. Any side effects are extremely unlikely. 
 
These samples will be grown in the laboratory to obtain the olfactory ensheathing cells, and 
then their properties will be tested in the laboratory or in animals to check that they are safe 
and are capable of repairing nerves. After study, the samples will be destroyed. 
Your GP will be informed if you decide to take part in the study. 
 
 
Do I have to take part? 
 
Your participation in this study is entirely voluntary. It is up to you to decide whether or not 
to take part. If you do decide to take part you will be given this information sheet to keep and 
be asked to sign a consent form. If you decide to take part you are still free to change your 
mind at any time without giving a reason. If you decide not to take part, this will not affect 
the standard of care that you will receive. 
 
 
What will happen to me if I take part? 
 
The biopsies will be taken during the operation. This theoretically may produce a small 
amount of bleeding, possible infection, or problems with the sense of smell on one side. 
However, these side effects are very unlikely to happen, and even if they did, would probably 
go unnoticed. The risks posed by taking the biopsies are far smaller than the risks of the 
standard operation that you are having. The specimens will go to the laboratory for further 
study, and will be destroyed at the end of the study. 
 
In addition, it is a requirement of the Human Tissue Authority to test donors for  
hepatitis B and C, syphilis, HIV and Human T-lymphotropic virus Type I and II 
(HTLV-1+2) before we take the specimen to our laboratory. This is to reduce infection 
risk and contamination in the laboratory. The results of these tests will be strictly 
confidential. 
 
This study will not affect the time you spend in hospital or your after-care, and no extra out-
patient reviews are required. Your sense of smell will be routinely checked at out-patient 
review.  
 
 
What are the benefits to taking part? 
 
There will be no direct clinical benefit for those patients undergoing biopsy during their 
pituitary operation. This study will be part of a bigger project to find a cure for paralysis that 
result from spinal cord or nerve injury. In the future it may help us to treat patients with 
spinal injuries.  
 
 
Confidentiality 
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The information gathered during this study will be strictly confidential, and stored on a 
password-protected hospital computer for future analysis. The information stored will include 
patients’ names, ages, types of operation and pathology results. The samples will be 
anonymised, but linked to patient data and analysed by Mr David Choi. The custodian of the 
data will be UCLH Foundation Trust, and Mr Choi will be responsible for the security of the 
data. Data will not be transmitted outside the European Union and will not be stored longer 
than 10 years. Any publication of data will not identify you in any way. 
 
 
 
 
 
Further questions? 
 
If you have any further questions about the study, we would be delighted to answer them for 
you. Please contact Mr David Choi via the National Hospital for Neurology and 
Neurosurgery, Tel. 020 3448 3395.  
 
This study has been reviewed by the National Hospital for Neurology and Neurosurgery and 
Institute of Neurology Joint Research Ethics Committee. 
 
 
What if something goes wrong? 
 
If you are harmed by taking part in this research project, there are no special compensation 
arrangements. If you are harmed due to someone’s negligence then you may have grounds for 
a legal action but you may have to pay for it. Regardless of this, if you wish to complain, or 
have any concerns about any aspect of the way you have been approached or treated during 
the course of this study, the normal National Health Service complaints mechanisms should 
be available to you. 
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Centre Number: 01 
Study Number: 8406 
Patient Identification Number for this trial: 
 
CONSENT FORM 
     Version 6. 26.04.15 
 
THE SOURCE, CULTURE AND CHARACTERISATION OF HUMAN 
OLFACTORY ENSHEATHING CELLS OBTAINED FROM BIOPSIES OF NASAL 
MUCOSA. 
 
Name of Researcher:            Please initial box 
 
1.    I confirm that I have read and understand the information sheet dated 26.04.15           
 (Version 6) for the above study and have had the opportunity to                    
 ask questions.          
 
2. I understand that my participation is voluntary and that I am free to withdraw             
at any time, without giving any reason, without my medical care or legal rights  
being affected. 
 
3. I understand that sections of any of my medical notes may be looked at by                  
 responsible individuals from UCLH, RNTNE Hospital, or from regulatory authorities where it is  
relevant to my taking part in research.  I give permission for these individuals to have access to my records. 
 
4. I agree to take part in the above study.                    
   
 
 
 
 
 
 
________________________ ________________ ______________ 
Name of Patient Date Signature 
 
 
_________________________ ________________ ______________          
Name of Person taking consent Date Signature 
(if different from researcher) 
 
 
_________________________ ________________ ______________ 
Researcher Date Signature 
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CONFIDENTIAL 
 
GP Information Sheet 
Version 3 
26
th
 April 2015 
 
THE SOURCE, CULTURE AND CHARACTERISATION OF HUMAN 
OLFACTORY ENSHEATHING CELLS OBTAINED FROM BIOPSIES OF NASAL 
MUCOSA. 
 
Dear Dr 
 
Your patient ………………………….. d.o.b……………………………… has agreed to take 
part in the above study. 
 
 
Background to the study 
 
“Olfactory ensheathing cells” are a unique group of cells that are found in the brain and nose, 
which can repair damaged nerve fibres. If these cells are transplanted into patients with 
damaged nerves or spinal cords, it may be possible to cure injuries which were previously 
untreatable. If we can learn how to obtain these cells from the nose and purify them in the 
lab, then in the future it might be possible to take cells from the nose of a patient with spinal 
cord injury and place them into the spine to help repair the damage and make them walk 
again.  
 
However it is first necessary to find a safe and reliable way to obtain these cells from 
patients, and check if they can repair nerves in a similar way to previous laboratory and 
animal studies. We are studying a method for obtaining and growing these cells, taken from 
the inside of the nose, close to the pituitary area in patients who are scheduled for 
transphenoidal pituitary surgery or nasal endoscopic surgery. 
 
 
What will be involved? 
 
The pituitary or endoscopic operation will not be affected. The only difference is that two 
small biopsies of mucosa, about 3-4mm cubes, will be taken from the inside of the nose 
during the surgery, on the way to the pituitary gland. Any side effects are extremely unlikely. 
Theoretically there may be a small risk of bleeding, possible infection, or problems with the 
sense of smell on one side. However, these side effects are very unlikely, and even if they did 
occur would probably go unnoticed. The risks posed by taking the biopsies are far smaller 
than the risks of the pituitary or nasal operation itself.  
 
This study will not affect the duration of the hospital admission or the after-care, and no extra 
out-patient reviews are required. 
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These samples will be cultured in the laboratory to obtain the olfactory ensheathing cells, and 
then their properties will be tested in the laboratory. 
 
 
What are the benefits to taking part? 
 
There will be no direct clinical benefit for those patients undergoing biopsy during their 
pituitary or nasal operation. This study will be part of a bigger project to find a cure for 
paralysis that results from spinal cord or nerve injury. In the future it may help us to treat 
patients with spinal injuries.  
 
 
Further questions? 
 
If you have any further questions about the study, we would be delighted to answer them for 
you. Please contact Mr David Choi via the National Hospital for Neurology and 
Neurosurgery Tel. 020 3448 3395. 
 
This study has been reviewed by the National Hospital for Neurology and Neurosurgery and 
Institute of Neurology Joint Research Ethics Committee. 
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